

**CONTINUING APPLICATION TRANSMITTAL UNDER RULE 1.53(b)
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

ARENT FOX KINTNER PLOTKIN & KAHN, PLLC
1050 Connecticut Avenue, N.W.,
Suite 600
Washington, DC 20036-5339
Telephone: (202) 857-6000
Facsimile: (202) 638-4810

Docket No. P100564-00030
Date: October 10, 2000

Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith for filing under 37 C.F.R. §1.53(b) is a

☐ Continuation ☒ Divisional ☐ Continuation-in-Part

application of prior pending Application No. 09/218, 176 filed December 22, 1998,

For (Title): A METHOD OF TREATMENT WITH GROWTH/DIFFERENTIATION FACTORS OF THE TGF- β FAMILY

By (Inventors): Gertrud HÖTTEN, Helge NEIDHARDT, Rolf BECHTOLD, Jens POHL, Michael PAULISTA

1. ☒ A Declaration and Power of Attorney is attached. The attached Declaration and Power of Attorney is:
 - ☒ a. A copy of the Declaration and Power of Attorney from the parent application. (Used with the same or fewer inventors and (a) a copy of the prior application or (b) a revised, reformatted or edited version of the prior application that does not contain new matter.)
 - ☐ b. A new Declaration and Power of Attorney. (Used with the same, fewer or additional inventors and (a) a copy of the prior application, (b) a revised, reformatted or edited version of the prior application that does not contain new matter, or (c) a new specification.)
2. ☒ The filing fee based on entry of the concurrently filed Preliminary Amendment is calculated below:

CLAIMS IN THE APPLICATION AFTER ENTRY OF
ANY PRELIMINARY AMENDMENT NOTED BELOW

FOR:	NO. FILED	NO. EXTRA
BASIC FEE		
TOTAL CLAIMS	05 - 20	= 0
INDEP CLAIMS	01 - 3	= 0
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS PRESENTED		

* If the difference is less than zero, enter "0".

SMALL ENTITY

RATE	FEE
	\$ 355
x 9 =	\$ 00
x 40 =	\$ 00
+135 =	\$ 00
TOTAL	\$ 00

OR
OR
OR
OR
OR
OR

**OTHER THAN A
SMALL ENTITY**

RATE	FEE
	\$ 710
x 18	\$ 00
x 80	\$ 00
+270	\$ 00
TOTAL	\$ 710

3. ☒ A Check in the amount of Seven Hundred Ten Dollars (\$710) to cover the filing fee is attached. The Commissioner is hereby authorized to charge any other fees that may be required to complete this filing, or to credit any overpayment, to Deposit Account No. 01-2300.
4. ☐ Cancel claim of the application before calculating the filing fee. At least one independent claim is retained for filing purposes.
5. ☒ Amend the specification by inserting before the first line the sentence:

--This is a ☐ Continuation ☒ Division ☐ Continuation-in-Part of Application No. 09/218,176 filed December 22, 1998, which in turn is a Continuation Application of Parent Application No. 08/679,048 filed July 12, 1996, which is a continuation-in-part of U.S. Serial Number 08/482,557

10/10/00
Jc891 U.S. PTO


Jc913 U.S. PTO
09/684383
10/10/00

filed July 6, 1995. The disclosure of the prior application(s) is hereby incorporated by reference herein in its entirety.--

6. ☒ Formal drawings (Figs. 1-9) are attached.
7. ☒ Priority of foreign application Nos. 91 102 324.8, P44 23 190.3 and 195 11 243.1 filed December 2, 1992, July 1, 1994 and March 27, 1995 in Europe, Germany and Germany are claimed under 35 U.S.C. §119 and/or §365(b).
8. ☒ The certified copy was filed in prior Application No. 08/482,557 on July 6, 1995.
9. ☐ A certified copy of the above foreign application(s) is attached.
10. ☐ Priority of U.S. Provisional Application(s) No. -- filed -- is claimed under 35 U.S.C. §119(e).
11. ☐ Amend the specification by inserting before the first line the sentence:
--This nonprovisional application claims the benefit of U.S. Provisional Application(s) No.-- filed --,--
12. ☒ The prior application is assigned of record to Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka MBH recorded at Reel 8294, Frame 0598 on November 4, 1996.
13. ☐ This application is filed by fewer than all the inventors named in the prior application (37 C.F.R §1.53(b)(1)). Delete the following inventor(s) named in the prior application:
14. ☒ A Preliminary Amendment is attached.
15. ☒ An Information Disclosure Statement is attached along with Form PTO-1449.
16. ☒ The Power of Attorney in the application is to Robert B. Murray, Reg. No. 22,980; Charles M. Marmelstein, Reg. No. 25,895; George E. Oram, Jr., Reg. No. 27,931; Douglas H. Goldhush, Reg. No. 33,125; David T. Nikaido, Reg. No. 22,663; Monica Chin Kitts, Reg. No. 36,105; Richard J. Berman, Reg. No. 39,107;.
17. ☒ Change of Address, Substitute Declaration
18. ☒ Address all future communications to:

ARENT FOX KINTNER PLOTKIN & KAHN, PLLC
1050 CONNECTICUT AVENUE, N.W.,
SUITE 600
WASHINGTON, D.C. 20036-5339

Respectfully submitted,


Robert B. Murray
Registration No. 22,980

ARENT FOX KINTNER PLOTKIN & KAHN, PLLC
1050 Connecticut Avenue, N.W.,
Suite 600
Washington, D.C. 20036-5339
Tel: (202) 857-6000
Fax: (202) 638-4810

RBM/cb

CK # 302327

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Gertrud HÖTTEN et al

Group Art Unit: 1646 (parent)

Application No.: Unknown

Examiner: P. Mertz (parent)

Filed: October 10, 2000

Attorney Dkt. No.: P100564-08026

For: A METHOD OF TREATMENT WITH GROWTH/DIFFERENTIATION FACTORS
OF THE TGF- β FAMILY

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

October 10, 2000

Sir:

Prior to calculation of the filing fee and prior to the examination of this application,
please amend the above-identified application as follows:

IN THE CLAIMS:

Cancel claims 1-23 without prejudice and insert the following new claims:

--24. An isolated protein of the TGF- β family which is coded by a DNA molecule
selected from the group consisting of

(a) a molecule comprising the nucleotide sequence shown in the SEQ ID No.
1, or the following fragments: nucleotides 128-1183, nucleotides 836-1183, nucleotides
128-835, and nucleotides 886-1183;

(b) a molecule comprising the nucleotide sequence shown in SEQ ID No. 3,
or the following fragments: nucleotides 131-1186, nucleotides 839-1186, nucleotides
131-838, and nucleotides 869-1186;

- (c) a molecule encoding the amino acid sequence encoded by (a) or (b);
- (d) a nucleotide sequence which differs from sequence (a), (b) or (c) due to its origin from other mammals wherein said nucleotide sequence hybridizes with one of the sequences from (a), (b), or (c) under stringent hybridization conditions in 6x SSC at 62-66° C followed by one hour wash with 0.6x SSC and 0.1% SDS at 62-66°; and
- (e) a nucleotide sequence which hybridizes with one of the sequences from (a), (b), (c) or (d) under stringent hybridization conditions in 6x SSC at 62-66° followed by one hour wash with 0.6x SSC and 0.1% SDS at 62-66°C.

25. The protein according to claim 24, wherein said protein has an amino acid sequence selected from the group consisting of SEQ ID NO: 2; SEQ ID NO: 4; the part of SEQ ID NO: 2 corresponding to the mature protein; the part of SEQ ID NO: 4 corresponding to the mature protein and sequences containing conservative substitutions of the amino acids shown in SEQ ID NO: 2 and SEQ ID NO: 4.

26. A heterodimeric protein comprising a monomer of the protein of claim 24 and a monomer of another protein from the superfamily with a "cysteine knot motif".

27. A pharmaceutical composition comprising the protein of claim 24 and pharmaceutical acceptable carrier or auxiliary substances, diluents or fillers.


28. A pharmaceutical composition comprising the protein of claim 26 and pharmaceutically acceptable carrier or auxiliary substances, diluents or fillers.--

REMARKS

The above amendment to the claims has been made to correct the multiple dependency of the claims and to put the application in better condition for examination.

Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300.

Respectfully submitted,



Robert B. Murray
Registration No. 22,980

ARENT FOX KINTNER PLOTKIN & KAHN, PLLC
1050 Connecticut Avenue, N.W.,
Suite 600
Washington, D.C. 20036-5339
Tel: (202) 857-6000
Fax: (202) 638-4810
RBM/cb

Description

The present invention concerns a new growth/ differentiation factor of the TGF- β family and DNA sequences coding therefor.

The BMP-, TGF- and inhibin-related proteins are members of the TGF- β family of growth factors (Roberts and Sporn, Handbook of Experimental Pharmacology 95, 419-472 (1990)). They are relevant for a wide range of medical therapeutic methods and applications. These factors are suitable for methods relating to wound healing and tissue regeneration. Moreover several members of the TGF- β family induce tissue growth for example the growth of bones.

Wozney (Progress in Growth Factor Research 1 (1989), 267-280) and Vale et al. (Handbook of Experimental Pharmacology 95 (1990), 211-248) describe various growth factors for example those which are related to the BMP and the activin/inhibin group. The members of this group have significant structural similarities. The precursor of the protein is composed of an amino-terminal signal sequence, a propeptide sequence and a carboxy-terminal sequence of 110 to 140 amino acids which is cleaved from the precursor and represents the mature protein. Furthermore its members are defined by an amino acid sequence homology. The mature protein contains the sequences that are conserved most, in particular seven cysteine residues which are conserved among the family members. The TGF- β -like proteins are multifunctional, hormonally active growth factors. They also have related biological activities for example chemotactic attraction of cells, promotion of cell differentiation and tissue-inducing capabilities. EP O 222 491 A1 discloses sequences of inhibin alpha and beta chains.

On the whole the proteins of the TGF- β family show differences in their structure which leads to considerable variations in

their exact biological function. In addition they are found in a wide range of different types of tissues and stages of development. As a consequence they may be different with regard to their exact function e.g. the required cellular physiological environment, their life span, their target areas, their requirements for auxiliary factors and their resistance to degradation. Although numerous proteins that show tissue-inductive potential have been described, their natural functions in the organism and - even more importantly - their medical relevance still has to be researched in detail. It can in all probability be assumed that there are still unknown members of the TGF- β family which are of importance for the differentiation/induction of various types of tissue. However, a major difficulty in the isolation of these new TGF- β -like proteins is that their functions cannot yet be described precisely enough to develop a highly discriminating bioassay. On the other hand the expected nucleotide sequence homology to known members of the family is too small to enable screening by classical nucleic acid hybridization techniques. Nevertheless the further isolation and characterization of new TGF- β -like proteins is urgently required in order to provide further inducing and differentiation proteins which fulfil all medical requirements. These factors could be used medically in healing injuries and treating degenerative diseases of various tissues.

A nucleotide and amino acid sequence for the TGF- β protein MP121 is given in the patent application PCT/EP93/00350 in which a major part of the sequence corresponding to the mature protein is stated. The complete sequence of the propeptide MP121 is not disclosed.

The underlying object of the present invention is to provide DNA sequences which code for new members of the TGF- β protein family with mitogenic and/or differentiation-inductive potential. The object of the present invention is in

particular to provide the complete DNA and amino acid sequence of the TGF protein MP121.

This object is achieved by a DNA molecule that codes for a protein of the TGF- β family and which comprises

- (a) the part coding for the mature protein and if necessary further functional parts of the nucleotide sequence shown in SEQ ID NO. 1,
 - (b) a nucleotide sequence corresponding to the sequence from (a) within the scope of the degeneracy of the genetic code,
 - (c) a nucleotide sequence corresponding to an allelic derivative of one of the sequences from (a) and (b) or
 - (d) a sequence which differs from sequence (a) due to the fact that it originates from other vertebrates
 - (e) a sequence hybridizing with one of the sequences from (a), (b), (c) or (d)
- provided that a DNA molecule according to (e) contains at least the part coding for a mature protein of the TGF- β family.

Further embodiments of the present invention concern the subject matter of claims 2 to 10. Other features and advantages of the invention emerge from the description of the preferred embodiments. The sequence protocols and drawings are now briefly described.

SEQ ID NO. 1 shows the complete nucleotide sequence of the DNA coding for the human TGF- β protein MP121. The ATG start codon begins at nucleotide 128. The start of the complete mature protein particularly preferably begins at nucleotide 836.

SEQ ID NO. 2 shows the complete amino acid sequence of the preproprotein of the human TGF- β protein MP121 which was derived from the nucleotide sequence shown in SEQ ID NO. 1. The start of the mature protein is preferably in the region of

amino acids 217-240, particularly preferably at amino acid 236 or 237 and most preferably at amino acid 237.

SEQ ID NO.3 shows the complete nucleotide sequence of the DNA coding for the TGF- β protein MP121 from the mouse. The coding region begins at the ATG start codon at nucleotide 131 and ends at the stop codon beginning at position 1187. The start of the mature protein preferably begins at nucleotide 839. A ca. 5.5 kb large intron is located in the genomic DNA between position 446 and 447.

SEQ ID NO. 4 shows the complete amino acid sequence of the preproprotein of the TGF- β protein MP121 from the mouse which has been derived from the nucleotide sequence shown in SEQ ID NO. 3. The mature protein begins in the region of amino acids 217-240 in analogy to the human MP121 of SEQ ID NO.2. It is most preferred when the mature protein starts at amino acid 237 so that the mature part consists of 116 amino acids as in the human MP121. Members of the TGF- β family are frequently cleaved behind a RXXR cleavage site in order to separate the mature part from the precursor (see Özkaynak et al., J. Biol. Chem. 267, 25220-25227 (1992) and the literature cited therein). In the case of MP121 from the mouse it is also conceivable that the beginning of the mature protein is at least sometimes at amino acid 236.

SEQ ID NO.5 shows the nucleotide sequence of the human MP121 gene at the exon/intron junctions. The nucleotides from both exons are marked by capital letters those of the intron by small letters.

Figure 1 shows a comparison of the amino acid sequence of human MP121 with some members of the TGF- β family (inhibin α and β chains) starting at the first of the seven conserved cysteine residues. * denotes that the amino acid is the same in all compared proteins; + denotes that the amino acid

corresponds in at least one of the proteins compared to human MP121.

Figure 2 shows the nucleotide sequences of the oligonucleotide primers which were used in the present invention and a comparison of these sequences with known members of the TGF- β family. M denotes A or C, S denotes C or G, R denotes A or G and K denotes G or T. 2a shows the sequence of primer OD, 2b shows the sequence of primer OID.

Figure 3 shows a diagram of a Western blot using chicken antibodies against human MP121.

Figure 4 shows the expression of MP121 compared to activin β_A and β_B in various mouse tissues.

Figure 5 shows a positive influence on the survival of dopaminergic neurones by treatment with partially purified MP121.

Figure 6 shows a Western blot using rabbit antibodies against human MP121.

Figure 7 shows the stimulation of nerve fibre outgrowth from the embryonic retina by treatment with partially purified MP121.

Figure 8 shows that partially purified MP121 can inhibit EGF induced DNA synthesis in hepatocytes.

Figure 9 shows the influence of partially purified MP121 on erythroid differentiation.

Within the scope of the present invention the term "mature protein" also encompasses functional partial regions of the complete protein which exhibit essentially the same biological activity and preferably those partial regions which include at

least the region of the seven cysteines that are conserved in the TGF- β family. In this case it is in particular possible that the N-terminus of the mature protein is slightly modified i.e. deviates from the sequences shown in SEQ ID NO.2 and 4. In this connection additional amino acids, which do not influence the functionality of the protein, may be present or amino acids may be absent provided that in this case the functionality is also not impaired. However, it is preferred that the human protein and the mouse protein contain all amino acids starting with amino acid 237 of the amino acid sequence shown in SEQ ID NO.2 and SEQ ID NO.4. It is already known from other family members of the TGF- β family that the attachment of additional amino acids to the N-terminus of the mature protein does not influence the activity wherein inter alia 6 additional histidines were attached to the N-terminus.

Therefore the present invention encompasses the part coding for the mature protein in accordance with the above-mentioned definition and if necessary, further functional parts of the nucleotide sequence shown in SEQ ID NO. 1 as well as sequences that correspond to this sequence within the scope of the degeneracy of the genetic code and allelic derivatives of such sequences. Furthermore the present invention also encompasses DNA sequences which code for a protein of the TGF- β family which were obtained from other mammals and which have a sequence that deviates slightly due to their origin but which, however, code for proteins having in principle the same biological function and also sequences that differ only slightly. Such sequences correspond to one another to a very large extent as can be seen by comparing SEQ ID NO. 1 and NO. 3.

In addition the present invention also covers sequences hybridizing with such sequences provided that such a DNA molecule at least completely contains the part coding for a mature protein of the TGF- β family (according to the above definition) and the biological activity is retained.

The term "functional part" within the sense of the present invention denotes a protein part which is capable of acting for example as a signal peptide, propeptide or mature protein moiety i.e. it fulfills at least one of the biological functions of the natural parts of MP121.

In the case of the preferred human MP121 the region coding for the mature part of the protein preferably extends from nucleotide 836 to the stop codon which begins at nucleotide 1184 of the sequence shown in SEQ ID NO. 1. If necessary, the DNA molecule can include further functional parts of the sequence shown in SEQ ID NO. 1 namely the nucleotide sequences coding for the signal or/and propeptide part. It is particularly preferred that the DNA molecule comprises the sequence for the signal and propeptide part and the mature protein part i.e. nucleotides 128 to 1184 of the sequence shown in SEQ ID NO. 1. In the case of the preferred mouse MP121 the region coding for the mature part of the protein preferably extends from nucleotide 839 to the stop codon starting at position 1187 of the sequence shown in SEQ ID NO.3. If desired the DNA molecule can also include further functional parts of the sequence shown in SEQ ID NO.3 i.e. if desired nucleotide sequences coding for the signal or/and propeptide part.

On the other hand the DNA molecules can also include functional signal or/and propeptide parts of other proteins e.g. of proteins with the cystine knot motif (Cell, vol. 73 (1993), p. 421-424) and in particular of other proteins of the TGF- β family e.g. the abovementioned activin/inhibin or BMP proteins especially also MP52 (see PCT/EP94/02630) in addition to the part coding for the mature protein. The respective nucleotide sequences can be found in the aforementioned references to the disclosure of which reference is herewith made. In this case it is important that the correct reading frame for the mature protein is preserved. Depending in which host cells expression takes place, the presence of another

signal sequence or/and of another propeptide part may positively influence the expression. The exchange of propeptide parts by corresponding parts of other proteins is described for example in Mol. Endocrinol. 5 (1991), 149-155 and Proc. Natl. Acad. Sci. USA 90 (1993), 2905-2909.

Although the allelic, degenerated and hybridizing sequences and sequences derived from other vertebrates which are covered by the present invention have structural differences due to slight changes in the nucleotide or/and amino acid sequence, proteins which are coded by such sequences still essentially have the same useful properties which enable them to be used in essentially the same medical fields of application.

According to the present invention the term "hybridization" denotes the usual hybridization conditions, preferably conditions with a salt concentration of 6 x SSC at 62 to 66°C followed by a one hour wash with 0.6 x SSC, 0.1 % SDS at 62 to 66°C.

Preferred embodiments of the present invention are DNA sequences as defined above which are obtainable from vertebrates, preferably mammals such as pigs, cows and rodents such as rats or mice and in particular from primates such as humans or which are copied from corresponding sequences.

A particularly preferred embodiment of the present invention are the sequences shown in SEQ ID NO. 1 and 3 and denoted human or mouse MP121 sequences. The transcripts of MP121 were obtained from liver tissue and code for a protein which shows a considerable amino acid homology to the mature part of the inhibin/activin-like proteins (see Figure 1). The protein sequences of human α -inhibin, inhibin β_A (activin β_A) and inhibin β_B (activin β_B) are described by Mason et al. (Biochem. Biophys. Res. Comm. 135, 957-964 (1986)). Some typical sequence homologies which are specific for known inhibin sequences were also found in the propeptide part of MP121

while other parts of the propeptide of MP121 show considerable differences to inhibin propeptides.

However previous findings show that there are differences between the pattern of expression of MP121 and that of the activins. While activins are mainly expressed in the gonads (activin β_A in ovaries and activin β_B in testes and ovaries), MP121 is mainly expressed in the liver. However up to now the sensitivity of the experiments has not been sufficient to also detect a slight expression. Thus in the case of activins it has for example been described in the literature that expression can also be detected outside the gonads in various rat tissues in adult animals (Meunier et al., Proc. Natl. Acad. Sci. USA 85, 247-251 (1988)) as well as during embryonic development (Roberts et al., Endocrinology 128, 3122-3129 (1991)). Therefore it is also possible that expression of MP121 in other tissues may yet be detected.

Because of the predominant expression of MP121 in liver the expression in one typical cell type of the liver was investigated in more detail. It was shown that the mRNA is expressed abundantly in cultured primary rat hepatocytes as well as in liver cell lines such as HepG2 (ATCC HB 8065). The expression in primary cells is markedly reduced by EGF (Epidermal Growth Factor) treatment after 60 hours. This pattern is completely different compared to activin β_A mRNA, which is barely expressed in hepatocytes but increased drastically after EGF treatment (Yasuda et al., J.Clin.Invest. Vol.92, 1491-1496 (1993)). Likewise, the expression of activin β_A mRNA and MP121 mRNA is reciprocal in remnant rat liver after 70% hepatectomy. MP121 mRNA is detected significantly before hepatectomy but is markedly decreased after 12 hours or later, whereas the mRNA for activin β_A is quite low before but elevated 12 hours or later after hepatectomy. Therefore MP121 seems to have a big influence on the ability of the liver to regenerate and proliferate. The control of MP121 mRNA expression and/or the amount of MP121 protein in liver can be

of significance for treatment of liver carcinomas, liver injuries or diseases such as for example cirrhotic liver.

In addition the present invention concerns a vector which contains at least one copy of a DNA molecule according to the invention. In such a vector the DNA sequence according to the invention is preferably linked operatively with an expression control sequence. Such vectors are suitable for producing TGF- β -like proteins in stably or transiently-transformed cells. Various animal, plant, fungal and bacterial systems can be used for the transformation and the subsequent culture. The vectors according to the invention preferably contain sequences necessary for replication in the host cell and they are autonomously replicable. In addition the use of vectors is preferred which contain selectable marker genes by which means the transformation of a host cell can be detected.

Furthermore the invention concerns a host cell which is transformed with a DNA according to the invention or with a vector according to the invention. Examples of suitable host cells include various eukaryotic and prokaryotic cells such as E. coli, insect cells, plant cells, mammalian cells and fungi such as yeast.

In addition the invention concerns a protein of the TGF- β family which is coded by a DNA sequence according to claim 1. The protein according to the invention preferably has the amino acid sequence shown in SEQ ID NO. 2 or in SEQ ID NO.4 or if desired functional parts thereof (as defined above) and exhibits biological properties such as tissue-inductive properties which may be relevant for a therapeutic application. The above-mentioned features of the protein can vary depending on the formation of homodimers or heterodimers with other proteins having the "cystine knot motif" and in particular TGF- β proteins. Such structures may also prove to be suitable for clinical applications and thus are also a subject matter of the present invention. Preferred

heterodimers include heterodimers composed of a monomer of the protein according to the invention and monomers of the α , β_A or β_B inhibin chains. The properties resulting from heterodimer formation can be shifted more towards the properties of activin or inhibins. If for example a heterodimer is formed with inhibin α proteins or with other inhibin β proteins, then it is assumed that the MP121/inhibin (α chain) or MP 121/activin (β_A or β_B chain) heterodimer can inhibit or activate the formation of follicle-stimulating hormone (FSH). MP121/activin heterodimers may also for example influence mesoderm development. Furthermore it is expected that heterodimeric forms with a member of the BMP group of TGF- β proteins lead to an amplification of BMP-like activities such as for example the ability to induce or promote bone formation, formation of cartilage or formation of connective tissue.

The invention therefore also concerns heterodimeric proteins of a protein of the TGF- β family according to the invention which is coded by a DNA sequence as claimed in claim 1 containing a monomer of a protein with the "cystine knot motif" preferably of another member of the TGF- β family. Similar heterodimeric proteins are described in W093/09229, EP 0 626 451 A2 and J. Biol. Chem. 265 (1990), 13198-13205.

In addition the invention concerns chimeric proteins which have functional derivatives or parts of a protein coded by a DNA sequence according to the invention preferably as shown in SEQ ID NO.2 or SEQ ID NO.4, in particular functional parts of the mature protein and additionally parts of another protein. In this case the other protein can also be a protein with a "cystine knot motif" which is preferably also a member of the TGF- β family such as e.g. especially MP52 (PCT/EP94/02630). However, parts of a complete different protein can also be present e.g. receptor-binding domains of proteins which lend the initial MP121 protein another specificity.

The biological properties of the proteins according to the invention, preferably MP121, can be determined for example in assays according to Wrana et al., (Cell 71, 1003-1014 (1992)), Ling et al. (Proc. Natl. Acad. of Science, 82, 7217-7221 (1985)), Takuwa et al. (Am. J. Physiol. 257, E797-E803 (1989)), Fann and Patterson (Proc. Natl. Acad. of Science, 91, 43-47 (1994)), Broxmeyer et al. (Proc. Natl. Acad. of Science, 85, 9052-9056 (1988)), Green et al. (Cell, 71, 731-739 (1992)) or Partridge et al. (Endocrinology, 108, 213-219 (1981)) or Krieglstein et al. (EMBO J. 14, 736-742 (1995)).

Activin A and TGF- β 1, TGF- β 2 and TGF- β 3 have been described to promote survival of dopaminergic neurones in vitro (Krieglstein et al., EMBO J. 14, 736-742 (1995) and Krieglstein et al., Neuroscience 63, 1189-1196 (1994)). In the case of partially purified MP121 it could be shown that the survival of dopaminergic neurones in a 8-day culture is promoted to a greater extent than by the influence of the control supernatant (Figure 5).

During the development of the visual system a projection of axons from the retinal ganglion cells to the special regions in the brain is established. It was shown by several groups that soluble factors isolated from visual areas of the brain can trophically stimulate retinal ganglion cells (Nurcombe, V. & Bennett, M.R., Exp. Brain Res. 44, 249-258 (1981), Hyndman, A.G., Adler, R., Dev. Neurosci. 5, 40-53 (1982), Turner, J.E. et al., Dev. Brain Res. 6, 77-83 (1983), Carri, N.G. & Ebendal, T., Dev. Brain Res. 6, 219-229 (1983)). The formation of nerve fibre fascicles, which most likely represent optic axons stemming from the retinal ganglion cells, depends on neurotrophic factors. Using MP121, a strong stimulation of retinal nerve fibre outgrowth in explant cultures of the embryonic chicken retina was evident as shown in Tab.1 and Figure 7. During these experiments, other members of the TGF- β superfamily, as for example MP52 (DE 195 25 416.3), were also proven to be active.

This activity of MP121 can be useful for the treatment of diseases at the eye as for example the retina or the optic nerve. It is especially useful for injuries of the neural retina and the optic nerve. Such injuries can be evoked for example by accidents, inflammations or disturbance of the supply of blood. It can also be useful for the transplantation of the retina. Furthermore the treatment of other cerebral nerves is important. One example is the trigeminal nerve (Nervus Trigeminus), which also provides parts of the eye. Therefore, members of the TGF- β family, especially MP52 and MP121, can also be useful for the transplantation of the cornea. Additionally the treatment of partial damage of the cornea as for example evoked by a herpes infection can be possible. Furthermore the treatment of degenerative disorders at the surface of the eye are of interest.

Results on rat hepatocytes in primary cultures indicate that partial purified MP121 inhibits the initiation of DNA synthesis (Figure 8). The effect of MP121 resembles that of Activin A and TGF- β (Yasuda et al., J. Clin. Invest. Vol. 92, 1491-1496 (1993)) but the concentrations of MP121 which are necessary to block the growth promoting actions of EGF are higher. Nevertheless it can be assumed that MP121 can influence liver growth. Therefore it can be useful in several liver diseases including liver carcinomas.

Activin A is furthermore known for its ability to promote the differentiation of Friend erythroleukemic cells (F5-5) wherefore it was also designated Erythroid differentiation factor (EDF) (Eto et al., Biochem. Biophys. Res. Com. 142, 1095-1103 (1987)). Partial purified MP121 shows also a slight activity in this assay system. Therefore MP121 can be useful in stimulation of erythropoiesis.

The present invention in addition concerns a process for the production of a protein of the TGF- β family which is characterized in that a host cell transformed with a DNA

according to the invention or with a vector according to the invention is cultured and the TGF- β protein is isolated from the cell or/and the culture supernatant. Such a process comprises culturing the transformed host cell in a suitable culture medium and purifying the TGF- β -like protein formed. In this way the process enables the production of an adequate amount of the desired protein for use in medical treatment or in applications using cell culture techniques in which growth factors are needed. The host cell can be a bacterium such as *Bacillus* or *E. coli*, a fungi such as yeast, a plant cell such as tobacco, potato or *Arabidopsis* or an animal cell, especially a vertebrate animal cell line such as Mo, Cos or CHO cell lines or an insect cell line. Using the Baculovirus system, expression can also be performed in insect larvae. When producing in bacteria it is possible that the protein according to the invention is produced in the form of inclusion bodies. These inclusion bodies are then renatured according to known methods and the protein is then obtained in an active form (see e.g. Jaenicke, R. and Rudolph, R., Protein Structure, ed. Creighton, T.E., JRL Press, chapter 9). For the production of heterodimeric proteins with other members of the TGF- β family, both protein monomers are expressed either in the same cell or separate in the course of which a common renaturation seems suitable with formation of inclusion bodies. Viral systems such as e.g. the Baculovirus system or the Vaccinia virus system are in particular suitable when coexpressing in the same cell. The production of heterodimeric proteins is in principle known to a person skilled in the art and is described for example in WO93/09229 and EP 0 626 451 A2.

The production of chimeric proteins containing other protein parts requires a corresponding change at the DNA level which is familiar to a person skilled in the art and can be carried out by him (EMBO J. 10 (1991), 2105-2110; Cell 69 (1992), 329-341; J. Neurosci. 39 (1994), 195-210).

Yet another subject matter of the present invention is the provision of pharmaceutical compositions which contain a pharmaceutically effective amount of a TGF- β -like protein according to the invention as the active substance. If desired, such a composition comprises a pharmaceutically acceptable carrier or auxiliary substance, diluent or filling agent. Such a pharmaceutical composition can be used alone or in combination with other active substances for example other proteins of the TGF- β family or growth factors such as EGF (epidermal growth factor) or PDGF (platelet derived growth factor) in wound healing and tissue regeneration. Furthermore such a pharmaceutical composition can be used for the prevention of diseases.

Further subject matters are pharmaceutical compositions which contain heterodimeric proteins or/and chimeric proteins according to the invention.

The pharmaceutical composition according to the invention is preferably used for the treatment and prevention of damage to bones, cartilage, liver, connective tissue, skin, mucous membranes, endothelium, epithelium, neurones, kidneys or teeth, for application in dental implants, for application in wound healing or tissue regeneration processes, induction of the proliferation of precursor cells or bone marrow cells, for the maintenance of a state of differentiation and for the treatment of disturbances in fertility or for contraception.

Furthermore the pharmaceutical composition according to the invention can be useful for the treatment of diseases concerning the metabolism, such as digestive disorders or disorders concerning the level of bloodsugar.

A further possible clinical application of the TGF- β -like protein according to the invention is the use as a suppressor of immunoreactions in order to avoid rejection of organ transplants or use in connection with angiogenesis.

Furthermore the protein according to the invention can be used to increase fertility or in contraception. The pharmaceutical composition according to the invention can also be used prophylactically or in cosmetic surgery. Furthermore the application of the composition is not limited to humans but can also include animals in particular pets and domestic animals.

Thus the part of the other protein or other monomer can be used to vary the scope of applications and specificity of heterodimeric proteins and chimeric proteins as desired.

In general diseases which are associated with the expression of MP121 can be treated using the proteins according to the invention either by increasing the amount or activity of MP121 which is present or by suppressing the MP121 activity. Thus the invention also concerns the production of antisense nucleic acids and ribozymes which inhibit the translation of MP121. This inhibition can either be achieved by masking the mRNA with an antisense nucleic acid or by cleavage with a ribozyme.

The production of antisense nucleic acids is known (Weintraub, H.M., Scientific American 262: 40 (1990)). The antisense nucleic acids hybridize with the respective mRNA and form a double-stranded molecule which can then no longer be translated. The use of antisense nucleic acid is for example known from Marcus-Sekura, C.J., Anal. Biochem. 172 (1988), p. 289-295.

Ribozymes are RNA molecules which are able to specifically cleave other single-stranded RNA molecules similar to DNA restriction endonucleases. The production of ribozymes is described in Cech, J. Amer. Med. Assn. 260 (1988), p. 3030.

In this connection it is also possible according to the invention to transfect suitable vectors containing the DNA

sequence according to the invention in vitro or in vivo into patient cells or to transfect the vectors in vitro into cells and then to implant these in a patient.

MP121 antisense polynucleotides can also be introduced into cells which exhibit an undesired expression of MP121.

The MP121 activity can also be suppressed by binding molecules to the MP121 receptors which, in contrast to MP121, do not trigger further transmission of a signal.

Thus within the scope of the invention the receptors for MP121 on cells are also of interest. In order to find receptors, firstly various cell lines can be tested for their binding properties with respect to radioactively labelled MP121 (¹²⁵I-MP121) with subsequent cross-linking. A cDNA library can subsequently be established in an expression vector (obtainable from InVitrogen) from cells which bind MP121. Cells which have been transfected with receptor cDNA can then be selected by the binding of radioactively labelled MP121. These are methods known to a person skilled in the art and have for example been used to isolate activin (Mathews, L.S. & Vale, W.W., Cell 65 (1991), 973-982) and TGF- β type II receptors (Lin, H.Y. et al., Cell 68 (1992), 775-785). In analogy to known activin receptors, the MP121 receptor is also presumably a receptor complex which belongs to this family so that further methods known to a person skilled in the art, such as e.g. PCR with degenerate oligonucleotides, can be used to find parts of the heteromeric complex. This method has also been used for example with the activin and TGF- β type I receptors (Tsuchida et al., Proc. Natl. Acad. Sci. USA 90 (1993), 11242-11246; Attisano et al., Cell 75 (1993), 671-680; Franzén et al., Cell 75 (1993), 681-692).

Finally the present invention concerns an antibody which can bind specifically to the proteins according to the invention or such an antibody fragment (e.g. Fab or Fab'). Processes for

the production of such a specific antibody or antibody fragment are part of the general knowledge of an average person skilled in the art. Such an antibody is preferably a monoclonal antibody. Such antibodies or antibody fragments can also be suitable for diagnostic methods.

In addition it is intended to illustrate the invention by the following examples.

Example 1

Isolation of MP121

1.1 Total RNA was isolated from human liver tissue (40 year old man) according to the method of Chirgwin et al. (Biochemistry, 18, 5294-5299 (1979)). Poly (A⁺)-RNA was separated from the total RNA by oligo (dT) chromatography according to the manufacturer's instructions (Stratagene poly (A) Quick columns).

1.2 For the reverse transcription reaction 1 to 2.5 µg poly (A⁺) RNA was heated for 5 minutes to 65°C and quickly cooled on ice. The reaction mixture contained 27 U RNA-Guard (Pharmacia), 2.5 µg oligo (dT)₁₂₋₁₈ (Pharmacia), 5 x buffer (250 mmol/l Tris/HCl pH 8.5, 50 mmol/l MgCl₂, 50 mmol/l DTT, 5 mmol/l of each dNTP, 600 mmol/l KCl) and 20 U AMV reverse transcriptase (Boehringer Mannheim) per µg poly (A⁺) RNA. The reaction mixture (25 µl) was incubated for 2 hours at 42°C. The cDNA pool was stored at -20°C.

1.3 The deoxynucleotide primers OD and OID shown in Figure 2 were prepared on an automatic DNA synthesizer (Biosearch). Purification was carried out by means of denaturing polyacrylamide gel electrophoresis and isolating the main bands from the gel by isotachopheresis. The oligonucleotides were designed by comparing nucleic acid sequences of known members of the TGF-β family and selecting regions with high conservation. A comparison of this region is shown in Figure

2. In order to facilitate cloning, both oligonucleotides contained Eco RI cleavage sites and OD additionally contained a Nco I restriction cleavage site at its 5' terminus.

1.4 In the PCR reaction cDNA corresponding to 20 ng poly (A+) RNA were used as starting material (see 1.2) The reaction was carried out in a volume of 50 μ l and contained 1 x PCR buffer (16.6 mmol/l $(\text{NH}_4)_2\text{SO}_4$, 67 mmol/l Tris/HCl pH 8.8, 2 mmol/l MgCl_2 , 6.7 μ mol/l EDTA, 10 mmol/l β -mercaptoethanol, 170 μ g/ml bovine serum albumin (Gibco), 200 μ mol/l of each dNTP (Pharmacia), 30 pmol of each oligonucleotide (OD and OID) and 1.5 U Taq polymerase (AmpliTa q , Perkin Elmer Cetus). The reaction mixture was overlayed with paraffin and 40 PCR cycles were carried out. The products of the PCR reaction were purified by means of phenol/chloroform extraction and concentrated by ethanol precipitation.

1.5 Half of the PCR reaction products was cleaved with the restriction enzymes SphI (Pharmacia) and AlwNI (Biolabs) according to the manufacturer's instructions. The other half was cleaved in a series of reactions using Ava I (BRL), AlwN I (Biolabs) and Tfi I (Biolabs). The restrictions were carried out in 100 μ l using 8 U enzyme for 2 to 12 hours at 37°C (apart from Tfi I at 65°C).

1.6 The products of the restriction cleavage were fractionated by means of agarose gel electrophoresis. After staining with ethidium bromide, uncleaved amplification products were cut out of the gel and isolated by phenol extraction. The DNA obtained was subsequently purified twice by phenol/chloroform extraction.

1.7 A quarter or a fifth of the isolated DNA was reamplified after ethanol precipitation using the same conditions as for the primary amplification except that the number of cycles was reduced to 13. The reamplification products were purified, cleaved with the same enzymes as above and uncleaved products

were isolated from the agarose gels as elucidated above for the amplification products. The reamplification step was repeated.

1.8 After the last isolation from the gel, the amplification products were cleaved by 4 U Eco RI (Pharmacia) under the conditions recommended by the manufacturer. A quarter of the restriction mixture was ligated into the vector pBluescript SK+ (Stratagene) which had been cleaved with Eco RI. After ligation, 24 clones of each enzyme combination were analyzed further by sequencing. There were no new sequences in the mixture which had been cleaved with AlwN I and Sph I, it contained only BMP6 and inhibin 8A sequences. 19 identical new sequences, named MP121, were found in the mixtures cleaved with Ava I, AlwN I and Tfi I. These plasmids were named pSK-MP121 (OD/OD). One sequence differed by two nucleotides from this sequence that was otherwise found. Ligation and transformation in *E. coli* was carried out as described in Sambrook et al., Molecular Cloning: A Laboratory Manual (1989).

The clone was extended to the 3' end of the cDNA according to the method described in detail by Frohmann (published by Perkin-Elmer Corp., Amplifications, 5, 11-15 (1990)). The same liver mRNA which had been used to isolate the first MP121 fragment was reversely transcribed as described above using oligo dT (16mer) linked to the adapter primer (AGAATTCGCATGCCATGGTCGACGAAGC -T₁₆). The amplification was carried out using the adapter primer (AGAATTCGCATGCCATGGTCGACG) and an internal primer (GGCTACGCCATGAACCTCTGCATA) prepared from the MP121 sequence. The amplification products were prepared using a further internal primer (ACATAGCAGGCATGCCTGGTATTG) prepared from the MP121 sequence and with the adapter primer. After restriction with Sph I the reamplification products were cloned into the vector pT7/T3 U19 (Pharmacia) which had been cleaved in the same way and sequenced. The clones were characterized by their

sequence overlap with the already known part of the MP121 sequence. One clone, named p121Lt 3' MP13, was used to isolate a Nco I (made blunt using T4 polymerase)/Sph I fragment. This fragment was cloned into one of the above-mentioned pSK-MP121 (OD/OID) vectors whose OD primer sequence was orientated towards the T7 primer of the pSK multiple cloning site. For this the vector was cleaved with SphI and SmaI. The construct was named pMP121DFus6. It comprises the MP121 sequence from position 922 to 1360 as shown in SEQ ID NO. 1.

1.9 A Dde I fragment of pMP121DFus6, which extends from position 931 to 1304 in SEQ ID NO. 1, was used to screen a human liver cDNA library (Clontech, # HL3006b, lot 36223) as described in detail by Ausubel et al., (Current Protocols in Molecular Biology published by Greene Publishing Associates and Wiley-Interscience (1989)). 24 mixed plaques were picked from 8.1×10^6 phages and separated. From this 10 clones which yielded a positive signal using primer LO2 (ACATAGCAGGCATGCCCTGCTATTG) and LO11 (CTGCAGCTGTGTTGGCCTTGAGA) from the Dde I fragment were selected and separated. The cDNA was isolated from the phages by means of an EcoRI restriction and cloned into the pBluescript SK vector which had also been cleaved with EcoRI.

Sequencing of one of the resulting plasmids SK121L9.1 showed that the start codon begins at position 128 of SEQ ID NO. 1 since three stop codons are positioned in-frame in front of this start codon at positions 62, 77 and 92. Mature MP121 starts at position 836 of SEQ ID NO. 1 assuming sequence analogy to other TGF- β proteins which corresponds to amino acid 237 in SEQ NO. 2. The stop codon begins at position 1184 of SEQ ID NO. 1.

Plasmid SK121L9.1 was deposited at the DSM on the 26.04.1994 under the deposit number 9177.

1.10 Isolation of the MP121 cDNA and genomic DNA from the mouse: The sequence information from the human MP121 sequence was used to isolate the MP121 sequence from the mouse. The methods used for this are all known to a person skilled in the art and are described for example in Current Protocols in Molecular Biology (Ausubel et al., Greene Publishing Associates and Wiley-Interscience, Wiley & Sons, 1987-1995) or in Molecular Cloning (Sambrook et al., second edition, Cold Spring Harbour Laboratory Press 1989). Firstly the primers ACGAATTCGACGAGGCATCGACTGC and GCGTCGACTACCATGTCAGGTATGTC derived from the human MP121 sequence containing additional restriction cleavage sites at the 5' end (EcoR I or Sal I) were synthesized. These primers were used for amplification on genomic mouse DNA. The 0.35 kb fragment which results was subcloned in the Bluescript vector (Stratagene) and used as a radioactive probe. A λ bank with genomic mouse DNA as well as a bank with cDNA was screened according to standard methods. The cDNA was synthesized from RNA, which had been isolated from mouse liver and cloned into λ gt10 using EcoR I/Not I linkers.

MP121 clones were isolated from the genomic as well as from the cDNA bank. A cDNA containing the complete coding sequence was subcloned into the EcoR I cleavage site of the Bluescript vector SK (Stratagene) and the resulting plasmid SKMP121 mouse was deposited on the 10.05.1995 at the DSM (DSM 9964). Complete sequencing resulted in the sequence shown in SEQ ID NO.3. The start codon begins at position 131 in SEQ ID NO.3 and ends at the stop codon starting at position 1187. The protein derived from the sequence is shown in SEQ ID NO.4. Subcloning and analyzing clones containing MP121 from the genomic bank showed that the MP121 sequence contains an intron in the propeptide part of ca. 5.5 kb. This intron is located between positions 446 and 447 in SEQ ID NO.3. The exon/intron junctions are shown in SEQ ID NO.5.

Example 2

Expression of MP121

It is possible to express MP121 in eukaryotic as well as in prokaryotic systems.

Only the mature part of MP121 was used for expression in prokaryotes. After purification the mature MP121 protein expressed in E. coli as a monomer can then be folded back to form a dimer. In order to simplify purification of MP121, an additional 6 histidines can be attached to the N-terminus of the mature protein which facilitate purification of the protein by binding to nickel-chelate columns.

As an example the mature part of human MP121 (amino acid 237 to 352 in SEQ ID NO.2) with an additional 13 amino acids, including 6 histidines at the N-terminus, (MHIIHHIIKKLEFAM) was expressed in the prokaryotic vector pBP4. This vector is a pBR322 derivative having tetracyclin resistance which in addition contains the T7 promoter from the pBluescript II SK plasmid (Stratagene). Furthermore the vector contains a ribosomal binding site following the T7 promoter and a start codon followed by 6 codons for histidine. A terminator (TØ) follows after several single restriction cleavage sites such as Eco RI, Xho I, Sma I and Apa I for the insertion of inserts as well as stop codons in all three reading frames. In order to obtain the cDNA for the mature part of MP121, PCR was carried out on the plasmid SK121L9.1 (DSM depositary number: 9177) using the two oligonucleotides GAATTTCGCCATGGCCATCGACTGCCAAGGAGG and CCGCTCGAAGCTTCAACTGCACCCACAGGC. Both oligonucleotides contain additional restriction cleavage sites at their ends (Eco RI and Nco I or Xho I and Hind III). In an intermediate step the resulting 377 bp fragment was cloned with blunt ends into the pBluescript II SK vector (Stratagene) that had been cleaved with Eco RV. One clone in the orientation of the 5' end of MP121 towards the T7 promoter was cleaved with Eco RI

and the resulting insert (0.38 kb) was cloned into the pBP4 vector that had also been cleaved with Eco RI. The correct orientation of the insert in the resulting plasmid pBP4MP121His was established by restriction analysis and sequencing. The plasmid pBP4MP121His was deposited on the 30.1.1995 at the DSM (depository number: 9704). The expression of MP121 protein can be achieved by simultaneously providing T7 RNA polymerase. T7 RNA polymerase can be provided by various methods such as e.g. by a second plasmid with a gene for T7 RNA polymerase or by infection with phages which code for T7 RNA polymerase or also by special bacterial strains which have integrated the gene for T7 RNA polymerase. The mature MP121 protein with a His-tag (MP121His) is produced in inclusion bodies by using the bacterial strain BL21 (DE3)pLysS (Novagen, #69451-1) and inducing the T7 RNA polymerase expression with IPTG according to the manufacturer's instructions. In SDS polyacrylamide gels (15 %) the protein exhibits an apparent molecular weight of nearly 16 kD (theoretical molecular weight: 14.2 kD) as is shown representatively in the Western blot of Fig. 3. The bacteria transformed with pBP4 as controls do not show any staining of specific bands. Due to the His-tag this protein can be purified on nickel-chelating agent columns as described for example by Hochuli et al., (BIO/Technology Vol. 6, 1321-1325 (1988)). An additional purification is possible by means of reversed phase HPLC. A reversed phase column (Nucleosil 300-7C4 from Macherey-Nagel, Type 715023) was used with a flow-rate of 2 ml/min and an acetonitrile gradient in 0.1 % TFA of 0 to 90 % within 100 minutes. MP121His elutes under these conditions after ca. 40 % acetonitrile.

The mature part of MP121 (amino acid 237 to 352 in SEQ ID NO.2) was additionally expressed in E.coli with one additional methionine at the N-terminus only using again a system with the T7 RNA Polymerase. The expression level was improved by including a gene for the lacI repressor in the expression plasmid (as it is used in the pET vectors from Novagen) and

using another *E. coli* strain, JMS 174 (DE3) (Novagen #69453). Inclusion bodies can be isolated by standard methods and washed with 2 M guanidinium chloride /HCL in 20 mM Tris pH 8.0. MP121 is further purified by a reversed phase HPLC as described for MP121His.

Additionally monoclonal antibodies were developed in mice. A peptide of 26 amino acids from the mature part of MP121 was used as an antigen: PLSILYYDRDSNIVKTDIPDMVVEAC. The antigen was coupled to ovalbumin using the free SH group of the cysteine according to conventional methods. Other constructs could be used as antigens also, as for example the dimeric mature MP121.

Immunization of BALB/c mice was performed according to conventional methods. The coupled peptide was used for example as antigen in combination with complete Freund's adjuvant for the first immunization and in combination with incomplete Freund's adjuvant in successive immunizations. The antigen (5-10 µg each time) was injected subcutaneously in the hind limbs of three mice at day 17, 14, 10, 7, 4 and 1 before the isolation of popliteal lymphatic nodes underneath the knee joint. A suspension of cells was produced for fusion to myeloma cells (P3x63Ag8.653, ATCC, CRL 1580) by the help of PEO. These techniques are described in more detail by Peters, J.H. & Baumgarten, H. (1990, Monoklonale Antikörper - Herstellung und Charakterisierung, Springer Verlag, 2.Auflage). It is possible to select for fused hybridomas by addition of azaserine and hypoxanthine. The supernatants of different wells were tested after 8-10 days with ELISA and Western blot analyses using MP121 expressed in eukaryotic and prokaryotic cells. The cells with the best positive results were further subcloned to isolate cells producing only one monoclonal antibody. To purify the monoclonal antibodies 1 liter of cell culture supernatant containing the monoclonal antibody was produced using roller bottles (Schott) in a "Cell-Roll" (Former Scientific) according to standard methods.

The antibodies of the cell culture supernatants can be concentrated and subsequently purified using a protein G column (ImmunoPure Plus (G) IgG Purification Kit, Pierce, #44795) according to the manufacturer's instructions. The monoclonal antibodies derived by this method proved to be useful for the detection of MP121.

In each case the determination whether it is MP121 protein was carried out by means of Western blot analysis using MP121-specific antibodies. Polyclonal antibodies against MP121 were produced in chicken as well as in rabbits. In order to obtain the antigen for the immunization, a part of the mature part of MP121 (amino acid 260 to 352 in SEQ ID NO.2) was fused with the first 98 amino acids of the polymerase of the MS2 bacteriophage and expressed in *E. coli*. After isolating the inclusion bodies, the fusion protein (MS2-MP121) was separated on polyacrylamide gels and isolated for the immunization after staining with copper by means of electro-elution (Tessmer, U. & Dernick, R., IBL (1990) 8-13). It is possible to specifically detect the expression of MP121 using antibodies from chicken as well as from rabbits. Chicken antibodies were used for the schematic Western blot in Figure 1 which had been purified further by means of PEG precipitation (Thalley B.S. and Carroll, S.B., BIO/Technology Vol. 8, 934-938 (1990)) and by means of membrane-bound antigen (fusion protein (MS2-MP121)) (18.17 in Sambrook et al., Molecular Cloning, second edition, Cold Spring Harbor Laboratory Press 1989). Anti-chicken IgG coupled to alkaline phosphatase (Sigma A9171) was used as the second antibody. The detection was carried out according to the manufacturer's instructions using the Tropix Western-Light Protein Detection Kit (Serva #WL10RC).

In order to obtain biologically active material, the purified monomeric MP121 expressed in *E. coli* can be folded back to form a dimeric MP121. This can be carried out according to the methods for example described by Jaenicke, R. & Rudolph, R.

(Protein structure, ed. Creighton, T.E., IRL Press, chapter 9).

The Vaccinia virus expression system was used for expression in eukaryotic cells as it is described in detail and in a form which can easily be repeated by a person skilled in the art in Current Protocols in Molecular Biology (Ausubel et al., Greene Publishing Associates and Wiley-Interscience, Wiley & Sons) abbreviated in the following as CP, in chapter 16 unit 16.15-16.18. The system is based on the fact that foreign DNA can be integrated by homologous recombination into the genome of the Vaccinia virus using certain vectors. For this purpose the vector used contains the TK (thymidine kinase) gene from the Vaccinia genome. In order to enable selection for recombinant viruses, the vector additionally contains the E. coli xanthine-guanine-phosphoribosyl transferase gene (gpt) (Falkner, F.G. & Moss, B., J. of Virol. 62 (1988), 1849-1854). The cDNA with the complete region coding for MP121 was cloned into this vector.

PCR reactions and intermediate cloning was necessary in order to shorten the 5' and 3' untranslated regions of the initial plasmid SK121L9.1 (DSM, depositary number: 9177) and to insert single restriction cleavage sites at the ends. All PCR reactions were carried out using the plasmid SK121L9.1 (DSM depositary number: 9177). In order to shorten the 5' untranslated end, the primer CCCGGATCCGCTAGCACCATGACCTCCTCATGCTTCTG with an inserted Bam HI and NheI restriction cleavage site was used in a PCR with an internal primer (CCCTGTTGCTCCTCTAGAAGTG). In an intermediate step the fragment obtained was cloned into Bluescript SK (Stratagene), sequenced and checked for concurrence with the sequence shown in SEQ ID NO.1. The Sph I/Eco RI fragment (0.22 kb) from the plasmid pBP4MP121His was used to shorten the 3' untranslated end.

Both end fragments of MP121 were linked to the missing middle DNA sequence from the plasmid SK121L9.1 (DSM depositary

The plasmid pBP1MP121 was used for the production of recombinant Vaccinia viruses. For this 143B cells (HuTk-, ATCC CRL 8303) which were 80 % confluent were infected with Vaccinia wild-type virus (1 virus per 10 cells) in 1 ml PBS in 35 mm culture plates for 30 minutes at room temperature while shaking occasionally. After aspirating the supernatant and adding 2 ml culture medium (MEM, Gibco BRL #041-01095 containing 1:500 diluted penicillin and streptomycin Gibco BRL #043-05140), they were incubated for 2 hours at 37°C. Subsequently the medium was removed and these cells were transformed for ca. 15 hours at 37°C using 100 ng pBP1MP121, 2 µg carrier DNA (calf thymus, treated with ultrasound, Boehringer Mannheim #104175) and 10 µl Lipofectin (Gibco BRL #18292-011) in 1 ml MEM. After addition of 1 ml MEM containing 20 % FCS (Sigma #P-7524) they were incubated for a further 24 hours at 37°C and subsequently the lysed cells were frozen.

Integration of the MP121 cDNA into the viral genome was confirmed by dot blot analysis (CP unit 16.18). A recombinant virus from the transfection with pBPMP121 and the wild-type

virus were used for expression analyses in cell lines 143B (HuTk-, ATCC CRL 8303, human) and NIH-3T3 (DSM ACC 59, Swiss mouse embryo). The cells were cultured according to the distributor's instructions. Confluent cells were infected for 30 minutes at 37°C with the three-fold number of viruses and subsequently the respective culture medium containing 10 % FCS and penicillin/streptomycin (1:500, Gibco BRL #043-05140) was added. The medium was removed after 6 hours at 37°C, the cells were washed twice with e.g. HBSS (Gibco BRL #14180-046) and production medium (MEM for HuTk- or DMEM containing 4.5 g/l glucose and NEAA (Gibco BRL #11140-035) for NIH-3T3 each of which contained aprotinin (Fluka #10820, 50 U/ml) and penicillin/streptomycin) without FCS. After a production period of 20 to 22 hours, the cell supernatant was collected. The expression was analysed by means of Western blots according to standard methods (CP unit 10.8). For this the proteins from 1 to 3 ml cell culture supernatant were precipitated by addition of an equivalent volume of acetone and incubating for at least one hour on ice and centrifuged. After resuspending the pellets in application buffer (7 M urea, 1 % SDS, 7 mM sodium dihydrogen phosphate, 0.01 % bromophenol blue and 1 % β -mercaptoethanol if desired) they were separated in 15 % polyacrylamide gels. A pre-stained protein molecular weight standard (Gibco BRL #6041-020) was used as marker proteins. Transfer onto a PVDF membrane (Immobilon #IPVH00010) and blocking the membrane was carried out according to standard methods.

A representative schematic diagram of the results of the Western blot in Figure 3 shows that MP121-specific bands occur in the recombinant virus infected cells. The expression of MP121 in NIH-3T3 cells leads to a secreted protein with an apparent molecular weight in the gel of about 18 kD under non-reducing conditions (expected theoretical molecular weight: 25 kD). Under reducing conditions the protein migrates at about 15 kD in the gel (expected theoretical molecular weight: 12.5 kD). These results show that MP121 is expressed

as a dimeric mature protein as expected. The migration behaviour of the dimeric MP121 protein which is only slightly slower than the monomeric MP121 protein is probably due to its globular structure. The processing of the precursor protein to form the mature protein could also be demonstrated in HuTk cells. No bands occurred in the Western blot with cells (HuTk- or NIH-3T3) infected with wild-type viruses (without integrated foreign DNA).

Further expression studies of MP121 using the Vaccinia virus system revealed that several cell lines express in addition to the dimeric MP121 also significant amounts of a monomeric form. This monomeric form seems to be folded and has a more globular structure because it runs faster in PAGE/Western blot analyses than the reduced monomer derived from the dimeric MP121 after treatment with DTT. Figure 6 shows the expression of dimeric and monomeric MP121 in HepG2 cells (Hepatocellular carcinoma, human, ATCC HB 8065). A residual unprocessed precursor form appears in addition. It was already shown by our Northern blot analysis that the HepG2 cells naturally transcribe the MP121 gene, therefore it can be assumed that the appearance of monomeric MP121 is of physiological relevance.

The monomeric MP121 was found besides the dimeric MP121 in significant amounts in Mv1Lu (NBL-7, lung, mink, ATCC CCL64) and Hela (Epitheloid carcinoma, cervix, human, ATCC CCL2) too. In addition, MP121 was expressed using the Baculovirus expression system (Invitrogen). After infection of insect larvae (*Trichoplusia ni*) with recombinant viruses, MP121 was detected in the haemolymph after 3-4 days in the dimeric form.

When co-transfection with recombinant Vaccinia viruses that code for various members of the TGF- β family has also taken place, the Vaccinia virus expression system is also particularly suitable for the production of heterodimers. It is then possible to separate heterodimers from homodimers by affinity columns using specific antibodies against the

individual members of the TGF- β family. In this case the α as well as β A and β B chains of inhibins are of particular interest.

Example 3

Investigation of the expression of MP121 in various mouse tissues

Total RNA from various tissues (brain, heart, kidney, liver, lung, spleen, muscle, ovary, testes) was isolated according to standard methods from 6 week-old mice as well as from embryonic stem cells. 10 μ g total RNA was used in each case in a RNase protection assay (RPA) from Ambion (RPA II kit, #1410) according to the manufacturer's instructions. In order to obtain specific probes for activin β_A and activin β_B the genomic DNA from the mouse (129Sv) was amplified from the mature part of the proteins using corresponding specific primers. In order to facilitate cloning, EcoR I and/or BamH I or Hind III restriction cleavage sites were introduced respectively at the ends of the primers. In the case of activin β_A the primers were derived from mRNA from rats (GenBank Accession #M37482);

GGATCCGAATTCGGCTTCGACTGTATGGCAACGG

and GGATCCGAATTCCTCTGGGACCTGGCAACTCTAG.

In the case of activin β_B degenerate primers were derived from the human sequence (Mason et al., Molecular Endocrinology 3, 1352-1358 (1989) :

GAGAAATCCCA(GA)CA(GA)TT(TC)TT(CT)AT

and GCAAGCTTT(GA)TA(TC)TC(GA)TC(GA)TC.

The resulting PCR fragments were subcloned into the vector pGEM-4 (Promega) and tested. The activin-specific and thus in the RPA protected sequences have a fragment size of 369 bp in the case of activin β_A and 254 bp in the case of activin β_B . In MP121 the protected fragment comprises the sequence from position 887 to position 1164 in SEQ ID NO.3. The fragments cloned into pGEM-4 were transcribed in vitro in order to produce radioactively labelled antisense RNA probes. This was

carried out according to the manufacturer's instructions (Promega, Riboprobe Gemini Systems) using 100 μ M CTP and at the same time α^{32} P-CTP (800 Ci/mmol, Amersham). A radioactively labelled RNA was also synthesized as a control from the plasmid pTri-GAPDH (Ambion #7431) linearized with Dde I but using 1 mM CTP. After isolating the 4 antisense RNA probes from polyacrylamide gels, these were incubated at 42°C overnight in the same mixture with the respective tissue RNA from the mouse (10 μ g total RNA per probe having 1×10^5 cpm). It was analyzed in a denaturing gel according to standard methods with a subsequent autoradiography for 4 days.

The analysis of MP121 mRNA expression in liver cells or remnant liver was performed likewise or using Northern blot analysis according to standard procedures (see CP, Chapter 4 or Molecular Cloning, Sambrook et al., 2nd Edition, Cold Spring Harbor Laboratory Press 1989).

Hepatocytes were isolated from rat (Wistar) liver and cultured according to Yasuda et al. (J. Clin. Invest. Vol. 92, 1491-1496 (1993)). The cells were washed prior to incubation with fresh serum-free medium containing 0.1 nM insulin, 0.1% BSA, optionally 1 nM EGF and (1 nM) partially purified MP121 (see Example 4).

Partial hepatectomy (about 70% of the rat liver) was performed as described by Higgins & Anderson (Arch. Pathol. 12, 186-202 (1931)) under ether anesthesia.

Example 4

Partial purification of MP121 and examination of the activity of partially purified MP121

The MP121 protein which had been obtained by expression in the Vaccinia virus system (see example 2) could be partially purified by means of two columns.

In order to produce MP121 confluent NIH-3T3 cells (DSM ACC 59, Swiss mouse embryo) were infected with the same number of

recombinant viruses for 30 minutes at 37°C and subsequently the appropriate culture medium containing 10 % FCS and penicillin/streptomycin was added.

After 4 hours at 37°C the medium was removed, the cells were washed twice and production medium (see Example 2) without FCS was added. After 20 to 22 hours production, the cell supernatant was collected and centrifuged in order to remove the viruses (40000 x g for 30 minutes at 4°C) and filtered (0.1 µm pore size, Millex VV, Millipore # SLVV25LS). The control supernatant (wt) was obtained in a comparable manner after infection by wild-type Vaccinia viruses. The expression of MP121 was checked by means of Western blot analysis and estimated to be 50-100 µg/l.

The cell culture supernatant containing MP121 (1.1 l) was admixed with the protease inhibitor PMSF (1 µM), brought to a final concentration of 1 M $(\text{NH}_4)_2\text{SO}_4$, 20 mM Tris pH 8.0 and loaded onto a phenyl-Sepharose (fast flow (high sub) Pharmacia #17-0973-05) column (5 ml bed) equilibrated in buffer A (1 M $(\text{NH}_4)_2\text{SO}_4$, 20 mM Tris pH 8.0). The loaded column was washed with 15 column volumes of buffer A and 10 column volumes of buffer B (20 mM Tris pH 8.0) and eluted within 50 minutes (5 ml per fraction) with a linear gradient to 100 % buffer C (20 mM Tris pH 8.0, 80 % ethylene glycol) at a flow rate of 1 ml/min. It was possible to check that MP121 eluted between 50 and 80 % ethylene glycol by means of Western blot analysis. Aliquots of these fractions were examined using 15 % polyacrylamide silver-stained gels according to the manufacturer's instructions (Silver Stain-II, Daiichi #SE140000) and the fractions containing MP121 were pooled. After purification of the control supernatant comparable fractions were also pooled after analysis in silver-stained gels.

The pooled fractions were purified further with the aid of reversed phase HPLC. For this a C8 column (Aquapore RP300, Applied Biosystems, particle size: 7 µm, pore size: 300Å) was

equilibrated with buffer A (0.1 % trifluoroacetic acid/water). After loading the column with the pooled fractions containing MP121 from the phenyl-Sepharose column, it was extensively washed with buffer A. The bound protein was eluted at a flow rate of 0.2 ml/min using a linear gradient of 1.5 % buffer B (90 % acetonitrile, 0.1 % trifluoroacetic acid) per minute. Fractions of 600 μ l were collected and analyzed in a Western blot as well as with silver-stained gels. Under the selected conditions MP121 protein eluted after about 55% acetonitrile. The fractions containing MP121 were pooled. The same was carried out with the corresponding fractions from the purification of the control supernatant. The analysis in the silver gel showed that MP121 was still contaminated by other proteins. Further purification steps are necessary to obtain pure MP121.

Other methods known to a person skilled in the art such as gel sieve columns, ion exchange columns, affinity columns or metal chelate columns could also be used for the further purification.

It was estimated from Western blot analysis that ca. 8 μ g partially purified MP121 was obtained from 1 l of cell culture supernatant. The partially purified protein was stored lyophilized at -80°C.

In order to investigate the influence of MP121 on dopaminergic neurones, neurones from the mesencephalic floor of 14 day-old rat embryos (E14) were isolated according to a method described by Shimoda et al. (Brain Res. 586, 319-331 (1992)). The cells were singled out and cultured as described by Kriegstein et al., (Neuroscience 63, 1189-1196 (1994)). The cell density on polyornithine/laminin-coated cover glasses is 200000 cells/cm². After culture for 24 hours and subsequently every three days two-thirds of the medium (500 μ l) was removed and replaced by fresh medium containing the respective additives. The lyophilized MP121 partially purified by phenyl

sepharose and reversed phase HPLC was dissolved in 50 % acetonitrile and added to the medium. The final concentration of MP121 in the medium is 20 ng/ml (the final concentration of acetonitrile is 0.3 %). A comparable amount from the control supernatant (wt) which had been purified in a comparable manner was dissolved in 50 % acetonitrile and added. The medium control also contains 0.3 % acetonitrile. After eight days the cultures were fixed for 10 minutes at room temperature in 4 % paraformaldehyde; the cells were made permeable with acetone (10 min, -20°C) and washed with PBS (phosphate buffered saline). After treatment with 1 % H₂O₂ in PBS, washing and blocking with horse serum, they were stained immunocytochemically. Tyrosine hydroxylase (TH) is a limiting enzyme in the biosynthesis of dopamine and other catecholamines so that TH can be used as a marker for dopaminergic neurones in the present cultures (cells containing noradrenaline were not isolated). TH was detected by a 1 hour incubation at 37°C using a mouse-monoclonal antibody against rat TH (diluted 1:200, Boehringer Mannheim) and subsequent detection using the Vectastair ABC kit (Vecto Labs). TH-positive cells were counted in an area of 0.12 cm². It can be seen from Fig. 5 that MP121 has a positive effect on the survival of dopaminergic neurones.

In order to investigate the neural influence of MP121 in another system explant cultures of the embryonic retina were used. This organotypic culture system is described in detail by Carri, N.G. & Ebendal, T. (Dev. Brain Res. 6, 219-229 (1983)), Carri, N.G. & Ebendal, T. (Anat. Rec. 214, 226-229 (1986) and Carri, N.G. et al. (J. Neurosci. Res. 19, 428-439 (1988)). This assay measures the stimulation of extending nerve fibres from the embryonic retina on a collagen substratum. Briefly, the retinal explants were taken from the chick retina (White Leghorn, embryonic day 6) and the neural retina was separated from the pigment epithelium and mesenchymal cells by repeated washing. The organotypic explants were transferred to collagen-coated culture dishes

and incubated overnight (37.5°C, 5% CO₂). The lyophilized MP121 partially purified by Phenyl-Sepharose and reversed phase HPLC was dissolved in aqueous buffer or 50% acetonitrile and diluted in the culture medium to a final concentration of 1.25 ng/ml, 12.5 ng/ml, 25 ng/ml, 50 ng/ml, 100 ng/ml, 200 ng/ml, whereby it makes no difference in the results whether acetonitrile or aqueous buffers were used for solubilization. A comparable amount from the control supernatant (wt) which had been purified in a comparable manner was added in control assays. For the background fibre outgrowth, standard tissue culture medium with only bovine serum added was used. The incubation was continued and after a 4 day period in culture the maximum length of the leading fascicles was measured in an inverted microscope under dark-field illumination. As shown in Table 1, MP121 dose-dependently stimulated the outgrowth of nerve fibres being maximally active at about 25 ng/ml resulting in a real fibre length of about 1.7 mm. Figure 7 shows the fibre outgrowth in a living culture after treatment with MP121 (5 ng/ml). The control (wt) did not stimulate fibre outgrowth as tested in concentrations equivalent to those used for the active MP121.

MP121 (ng/ml)	Length (units)	Mean±SEM
1.25	7/12/5/6	7.5±1.5
12.5	19/20/13/26	19.5±2.6
25	50/52/60/71/65/53	58.5±3.4
50	37/32/48/41/36/20	35.6±3.8
100	21/8/19/18	16.5±2.9
200	11/8/12/10	10.2±0.8

Table 1: Retinal neurite length after 4 days in culture treated with different concentrations of MP121. The neurite lengths of the background fibre outgrowth in the control tissue culture medium were 5.5/8/10/11/4.8/7 units giving a mean of 7.7 units (SEM 1.00). The neurite lengths of the wt control

(used in equivalent concentrations as MP121) was in the same range as the background fibres.

Each unit represents 0.03 mm real scale in the culture dish.

In order to investigate the influence of MP121 on liver derived cells hepatocytes were isolated from rat (Wistar) liver and cultured according to Yasuda et al. (J. Clin. Invest. Vol. 92, 1491-1496 (1993)). The cells were washed prior to incubation with fresh serum-free medium containing 0.1 nM insulin, 0.1% BSA and 1 nM EGF. The lyophilized MP121 partially purified by phenyl sepharose and reversed phase HPLC was solubilized in acetonitrile as usually and added to the medium at various concentrations (see Figure 8). A comparable amount from the control supernatant (wt) which had been purified in a comparable manner was used as a control. The hepatocytes were incubated for 72h and 0.5 μ Ci [3 H]Thymidine/ml was included for the last 24 hours as described by Mead & Fausto (Proc.Natl.Acad.Sci.USA 86, 1558-1562 (1989)). [3 H]Thymidine incorporation into trichloroacetic acid-precipitable material was subsequently measured as described by McNeil et al. (J.Cell Biol. 101, 372-379 (1985)).

In order to investigate the influence of MP121 on erythroid differentiation its influence on Friend leukemia cells (F5-5) was measured. Therefore Friend leukemia cells were cultured in microtiter plates essentially as described by Eto et al. (Biochem. Biophys. Res. Com. 142, 1095-1103 (1987)). The lyophilized MP121 partially purified by phenyl sepharose and reversed phase HPLC was solubilized as already described, added to the Friend cells at various concentrations (see Figure 9) and incubated for 5 days. The percentage of differentiated cells was determined after staining with o-dianicidine.

CLAIMS

We claim:

1. A DNA molecule that codes for a protein of the TGF- β family comprising:

(a) the part coding for the mature protein and if necessary further functional parts of the nucleotide sequence shown in SEQ ID NO. 1;

(b) a nucleotide sequence corresponding to the sequence from (a) within the scope of the degeneracy of the genetic code;

(c) a nucleotide sequence corresponding to an allelic derivative of one of the sequences from (a) and (b);

(d) a sequence which differs from sequence (a) due to its origin from other vertebrates; or

(e) a nucleotide sequence hybridizing with one of the sequences from (a), (b), (c) or (d) provided that a DNA molecule according to (e) at least completely contains the part coding for a mature protein of the TGF- β family.

2. The DNA molecule of claim 1, further comprising a nucleic acid sequence which codes for at least a part of another protein and which is arranged in such a way that after expression a fusion protein results.

3. A vector comprising at least one copy of a DNA molecule of claim 1.

4. A host cell comprising the DNA of claim 1.

5. The host cell of claim 4, selected from the group consisting of a bacterium, a fungus, a plant and an animal cell.

6. A protein of the TGF- β family which is coded by the DNA sequence of claim 1.

7. The protein of claim 6, which comprises an amino acid sequence selected from the group consisting of the sequence of SEQ ID NO. 2; SEQ ID NO. 4, and functional parts of the sequence of SEQ ID NO. 2 or SEQ ID NO 4.

8. A chimeric protein comprising the protein of claim 6 and at least a part of another protein.

9. A heterodimeric protein comprising a monomer of the protein of claim 6 and a monomer of another protein from the superfamily with a "cysteine knot motif".

10. A process for the production of a protein comprising

- a) culturing the host cell of claim 4, and
- b) obtaining the protein from the cell or/and the culture supernatant.

11. A process for the production of the heterodimeric protein of claim 9, wherein both monomers are coexpressed in a host cell.

12. A process for the production of the heterodimeric protein of claim 9, wherein a combined renaturation of inclusion bodies of both monomers is carried out.

13. A pharmaceutical composition comprising the protein of claim 6 as the active substance and pharmaceutically acceptable carrier or auxiliary substances, diluents or fillers.

14. The pharmaceutical composition of claim 13 for the treatment or prevention of damage to bones, cartilage, liver, connective tissue, skin, mucous membranes, endothelium, epithelium, neurones, brain, kidney or teeth, for application in dental implants, for use in wound healing or tissue regeneration processes, induction of the proliferation of precursor cells or bone marrow cells, for maintaining a state of differentiation and for the treatment of disturbances in fertility or for contraception or for the treatment of diseases concerning the metabolism.

15. The pharmaceutical composition of claim 14 for the treatment and/or prevention of diseases of the nervous system and/or for the treatment of neuropathological situations which are caused by the ageing of the nervous system.

16. The pharmaceutical composition of claim 15 for the treatment or prevention of diseases of the eye, in particular, of the neuronal layer of the retina, the cornea, the optic nerve and/or other nerves of the brain.

17. An RNA molecule which is an antisense RNA, which is complementary to a part of a DNA molecule of claim 1.

18. A ribozyme which specifically cleaves an RNA molecule which is obtained after transcription of the DNA molecule of claim 1.

19. The use of an antisense RNA of claim 17 for blocking the expression of a protein of the TGF- β family.

20. The use of a ribozyme as claimed in claim 18 for blocking the expression of a protein of the TGF- β family.

21. The use of the DNA sequence of claim 1 for the in vitro or in vivo transfection of patient cells.

22. Antibodies or antibody fragments which bind to the protein of claim 6.

23. A receptor which is specifically bound by the protein of claim 6.

ABSTRACT OF THE DISCLOSURE

The invention concerns a protein of the TGF- β family, the DNA coding therefor and a pharmaceutical composition containing such protein.

Fig. 1

	10	20	30	40
MP121	CCRQEFFVDF	REIGWHDWII	QPEGYAMNFC	IGQCPLHIAG
INHIB β A	CEKKQFFVSF	KDIGWNDWII	APSGYHANYC	EGECPSHIAG
INHIB β B	CCRQQFFIDF	RLIGWNDWII	APTGYGNYC	EGSCPAYLAG
INHIB α	CHRVALNISF	QELGWERWIV	YPPSFIFHYC	HGGCGLHIP-
	++*+*+*	+*+*+*+*	*+*+*+*	*+*+*+*
	50	60	70	80
MP121	MPGIAASFHT	AVLNLLKANT	AAGTTGGGSC	C--VPTARRP
INHIB β A	TSGSSLSFHS	TVINHYMRG	HSPFANLKSC	C--VPTKLRP
INHIB β B	VPGSASSFHT	AVYNQYMRG	LNP-GTVNSC	C--IPTKLST
INHIB α	---PNLSLPV	PGAPPTPAQP	YSLPGAQPC	CAALPGTMRP
	+*+*+*+*	+*+*+*	+*+*	*+*+*+*
	90	100	110	
MP121	LSLLYYDRDS	NIVKTD-IPD	MYVEACGCS	
INHIB β A	MSMLYYDDGQ	NIKKD-IQN	MIVEECGCS	
INHIB β B	MSMLYFDDEY	NIVKRD-VPN	MIVEECGCA	
INHIB α	LHVRTSDGG	YSFKYETVPN	LLTQHCACI	
	+*+*+*	+*+*+*	+*+*+*	

Fig. 2a

EcoRI HcoI

OD	ATGAATTC CATGGACCTGGGCTGGHAKGAMTGGAT
BMP 2	ACGTGGGGTGGAAATGACTGGAT
BMP 3	ATATTGGCTGGAGTGAATGGAT
BMP 4	ATGTGGGCTGGAAATGACTGGAT
BMP 7	ACCTGGGCTGGCAGGACTGGAT
TGF- β 1	AGGACCTCGGCTGGAAAGTGGAT
TGF- β 2	GGGATCTAGGGTGGAAATGGAT
TGF- β 3	AGGATCTGGGCTGGAAAGTGGAT
INHIBIN α	AGCTGGGCTGGGAACGGTGGAT
INHIBIN β_A	ACATCGGCTGGAAATGACTGGAT
INHIBIN β_B	TCATCGGCTGGAAAGTGGAT

Fig. 2b

EcoRI

OD	ATGAATTCGAGCTGGCTGGGSRACAGCA
BMP 2	GAGTTCTGTGGGACACAGCA
BMP 3	CATCTTTTCTGGTACACAGCA
BMP 4	CAGTTCAGTGGGACACAAACA
BMP 7	GAGCTGGCTGGGCGACAGCA
TGF- β 1	CAGCGCTTGGGACACAGCA
TGF- β 2	TAAATCTTGGGACACAGCA
TGF- β 3	CAGGTCTTGGGACACAGCA
INHIBIN α	CCCTGGGAGAGCAGCAGCA
INHIBIN β_A	CAGCTTGGTGGGACACAGCA
INHIBIN β_B	CAGCTTGGTGGGAATGCAGCA

Fig. 3




Figure 3: Diagram of a Western blot using chicken antibodies against MP121

1: E. coli cells transformed with pBP4MP121His under reducing conditions (1 % β -mercaptoethanol)
 2: Cell culture supernatant of NIH-3T3 cells after infection with recombinant viruses (with inserted MP121 cDNA) under reducing conditions (1 % β -mercaptoethanol)
 3: Cell culture supernatant of NIH-3T3 cells after infection with recombinant viruses (with inserted MP121 cDNA) under non-reducing conditions
 M: prestained protein molecular weight markers having the stated apparent molecular weights (Gibco BRL #26041-020)




Figure 4: Autoradiogram after gel analysis of a RNase protection assay using specific probes against activin β_A (β_A), activin β_B (β_B), MP121 and against GAPDH for the control.

Total RNA was tested which had been isolated from various mouse tissues (1: brain, 2: heart, 3: kidney, 4: liver, 5: lung, 6: muscle, 9: ovary, 10: spleen, 11: testes), from embryonic stem cells (12: CJ7) and from yeast (lane 13) as a control. No RNA was used in lane 14 as a control. The unprotected antisense RNA probes used for the hybridization are applied in lanes 8 and 15 and the expected fragment size is indicated in brackets in the right margin. The bands of the protected fragments are labelled in the left margin. pBR322

restricted with Msp I (Biolabs #303) and end-labelled with γ - 32 P-ATP (Amersham) was used as the marker (lane 7).




Fig. 5.

Figure 5 shows the number of TH-immunoreactive dopaminergic neurones surviving after isolation from the mesencephalon of rat embryos (E14) after 8 days culture. The effect of 20 ng/ml partially purified MP121 was tested compared to the equivalent amount of partially purified control supernatant (wt) as well as untreated neurones (control: medium containing 0.3 % acetonitrile). The mean \pm SEM from a triple determination is shown.




Figure 6: Western blot using rabbit antibodies against human MP121

- 1: cell culture supernatant of HepG2 cells after infection with recombinant viruses (with inserted MP121 cDNA) under non reducing conditions
- 2: cell culture supernatant of HepG2 cells after infection with wildtype viruses under non reducing conditions
- 3: prestained protein molecular weight marker having the apparent molecular weights of 15,5 / 18,2 / 27,8 / 43,8 / 71,5 kD (Gibco BRL #26041-020), indicated schematically
- 4: cell culture supernatant of HepG2 cells after infection with recombinant viruses (with inserted MP121 cDNA) under reducing conditions
- 5: cell culture supernatant of HepG2 cells after infection with wildtype viruses under reducing conditions




Figure 7: Nerve fibre outgrowth from explanted chicken retina after 4 days in culture in the presence of 5 ng/ml partially purified MP121. Dark-field microscopy of living cultures.

000101-000101000




Figure 8: Effect of various concentrations of partially purified MP121 on EGF induced DNA synthesis in hepatocytes




Figure 9: Effect of various concentrations of partially purified MP121 on erythroid differentiation measured by the percentage of dianisidine positive cells.

Declaration For U.S. Patent Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled
(Insert Title) NEW GROWTH/DIFFERENTIATION FACTOR OF TGF- α FAMILY
the specification of which

(Check one of blocks 1, 2 or 3. See note A on back of this page)

1. ☐ is attached hereto.
2. ☐ was filed on _____ as International PCT
Application Serial No. _____ and was amended on

(if applicable)
3. ☒ was filed on July 12, 1996 as U.S. Application
Serial No. 08/679,048 and was amended on

(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application for which priority is claimed:

(List prior foreign applications. See note B on back of this page)

92 102 324.8
(Number)
P 44 23 190.3
(Number)
195 11 243.1
(Number)
PCT/EP96/03065
(Number)

Europe
(Country)
Germany
(Country)
Germany
(Country)
PCT
(Country)

12/2/92
(Day/Month/Year Filed)
1/7/94
(Day/Month/Year Filed)
27/3/95
(Day/Month/Year Filed)
12/7/1996
(Day/Month/Year Filed)

Priority Claimed
☒ Yes ☐ No

☒ Yes ☐ No

☒ Yes ☐ No

☒ Yes ☐ No

(See Note C on back of this page)

☐ See attached list for additional prior foreign applications

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT International application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT International filing date of this application:

(List prior U.S. Applications or PCT International applications designating the U.S.)

PCT/EP93/00350
(Application Serial No.)
08/482,557
(Application Serial No.)

12/2/93
(Filing Date)
7/6/95
(Filing Date)

Pending
(Status) (patented, pending, abandoned)
Pending
(Status) (patented, pending, abandoned)

And I hereby appoint as principal attorneys David T. Nikaido, Reg. No. 22,663; Charles M. Marmelstein, Reg. No. 25,895; George E. Oram, Jr., Reg. No. 27,931; Robert B. Murray, Reg. No. 22,980; Martin S. Postman, Reg. No. 18,570; E. Marcie Emas, Reg. No. 32,131; Michael G. Gilman, Reg. No. 19,114; Douglas H. Goldhush, Reg. No. 33,125; Kevin C. Brown, Reg. No. 32,402; Monica Chin Kiuts, Reg. No. 36,105; Sharon Nolan Klesner, Reg. No. 36,335; John R. Fuisz, Reg. No. 37,327, and Richard J. Berman, Reg. No. 39,107..

Please direct all communications to the following address: **NIKAIDO, MARMELESTEIN, MURRAY & ORAM LLP**
Metropolitan Square
655 Fifteenth Street, N.W., Suite 330 - G Street Lobby
Washington, D.C. 20005-5701
(202) 638-5000 Fax: (202) 638-4810

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

(See Note D on back of this page)

Full name of sole or first inventor Gertraud HÖTTEN
Inventor's signature *Gertraud Höttén* 14.10.96
Residence Weihswiesenweg 17, Federal Republic of Germany, D-69245 Bammertal Date
Citizenship German
Post Office Address 69245 Bammertal, Federal Republic of Germany

Full name of second joint inventor, if any Helge NEIDHARDT
Inventor's signature Helge Neidhardt 16 Oct. '96
Residence Birkenweg 7, 35041 Marburg, Federal Republic of Germany ^{Date}
Citizenship German
Post Office Address Birkenweg 7, D-35041 Marburg, Federal Republic of Germany

Full name of third joint inventor, if any Rolf BECHTOLD
Inventor's signature Rolf Bechtold Oct 14, 96
Residence Carl-Zuckmayer-Straße 21, D-69126 Heidelberg, Fed. Rep. of Germany ^{Date}
Citizenship German
Post Office Address Carl-Zuckmayer-Straße 21, D-69126 Heidelberg, Fed. Rep. of Germany

Full name of fourth joint inventor, if any Jens POHL
Inventor's signature Jens Pohl 14.10.96
Residence Kellerswiesen 3, D-76707 Hambrücken, Fed. Rep. of Germany ^{Date}
Citizenship German
Post Office Address Kellerswiesen 3, D-76707 Hambrücken, Fed. Rep. of Germany

Full name of fifth joint inventor, if any Michael PAULISTA
Inventor's signature Michael Paulista 14.10.96
Residence Wingertstraße 10, D-69181 Leimen, Federal Republic of Germany ^{Date}
Citizenship German
Post Office Address Wingertstraße 10, D-69181 Leimen, Federal Republic of Germany

Full name of sixth joint inventor, if any _____
Inventor's signature _____ ^{Date}
Residence _____
Citizenship _____
Post Office Address _____

Full name of seventh joint inventor, if any _____
Inventor's signature _____ ^{Date}
Residence _____
Citizenship _____
Post Office Address _____

Full name of sixth joint inventor, if any _____
Inventor's signature _____ ^{Date}
Residence _____
Citizenship _____
Post Office Address _____

Declaration For U.S. Patent Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled
(Insert Title) NEW GROWTH/DIFFERENTIATION FACTOR OF TGF- β FAMILY

the specification of which is attached hereto unless the following box is checked:

☐ was filed on _____ as PCT International Application
Number _____ and was amended on _____
and/or was filed on December 22, 1998 as United States Application
Number 09/218,176 and was amended on _____

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate or PCT International Application having a filing date before that of the application(s) for which priority is claimed:

(List prior foreign applications. See note A on back of this page)	(Number)	U.S. (Country)	12/07/1996 (Day/Month/Year Filed)	Priority Claimed <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
	<u>08/679,048</u>	(Country)		
	<u>92 102 324.8</u>	Europe	12/2/92	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
	<u>P 44 23 190.3</u>	(Country)	(Day/Month/Year Filed)	
		Germany	1/7/94	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
	<u>195 11 243.1</u>	(Country)	(Day/Month/Year Filed)	
		Germany	27/3/95	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
	<u>PCT/EP96/03065</u>	(Country)	(Day/Month/Year Filed)	
		PCT	12/7/1996	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
	(Number)	(Country)	(Day/Month/Year Filed)	

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) or §365(c) of any PCT International application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior application(s) (U.S. or PCT) in the manner provided by the first paragraph of 35, U.S.C. §112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

(List prior U.S. Applications or PCT International applications designating the U.S.)	PCT/EP/93/00350 (Application Serial No.)	12/2/93 (Filing Date)	Pending (Status) (patented, pending, abandoned)
	<u>08/482,557</u>	7/6/95	Pending (Status) (patented, pending, abandoned)

And I hereby appoint as principal attorneys: Robert B. Murray, Reg. No. 22,980; Charles M. Marmelstein, Reg. No. 25,895; George E. Oram, Jr., Reg. No. 27,931; Douglas H. Goldhush, Reg. No. 33,125; David T. Nikaido, Reg. No. 22,663; Monica Chin Kitts, Reg. No. 36,105; Richard J. Berman, Reg. No. 39,107; King L. Wong, Reg. No. 37,500; James A. Poulos, III, Reg. No. 31,714; Murat Ozgu, Reg. No. 44,275; Bradley D. Goldizen, Reg. No. 43,637; N. Alexander Nolte, Reg. No. 45,689; Robert K. Carpenter, Reg. No. 34,794; Gregory B. Kang Reg. No. 45,273; and Rustan Hill Reg. No. 37,351.



Please direct all communications to the following address: ARENT FOX KINTNER PLOTKIN & KAHN, PLLC
1050 Connecticut Avenue, N.W., Suite 600
Washington, D.C. 20036-5339
Telephone No. (202) 857-6000; Facsimile No. (202) 638-4810

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

(See Note C on back of this page) Full name of sole or first inventor Gertrud HÖTTEN
Inventor's signature *Gertrud Hötten* 08.01.2000 DateResidence Weihenweg 17, Federal Republic of Germany, D 69245 BammertalCitizenship GermanPost Office Address 69245 Bammertal, Federal Republic of Germany44625 HERNE→ Hölkeskampweg 96, Federal Republic of Germany, D 44625 Herne*J. H. K.*

Inventor's signature X *Kelke Nach* *dt* X *14 August, 2000*
 Residence Birkenweg 7, 35041 Marburg, Federal Republic of Germany
 Citizenship German
 Post Office Address Birkenweg 7, 35041 Marburg, Federal Republic of Germany

Inventor's signature X Karl Ziemer X July 31, 2000
Date
Residence Carl-Zuckmayer-Straße 21, D-69126 Heidelberg, Federal Republic of Germany
Citizenship German
Post Office Address Carl-Zuckmayer-Straße 21, D-69126 Heidelberg, Federal Republic of Germany

Inventor's signature X  X  Date 31.12.2000

Residence Kellerswiesen 3, D-76707 Hambrücken, Federal Republic of Germany

Citizenship German

Post Office Address Kellerswiesen 3, D-76707 Hambrücken, Federal Republic of Germany

Inventor's signature X R. Ulrich 23.8.00 Date
Residence Wingertstraße 10, D-69181 Leimen, Federal Republic of Germany
Citizenship German
Post Office Address Wingertstraße 10, D-69181 Leimen, Federal Republic of Germany

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Gertrud HÖTTEN et al

Group Art Unit: 1646 (parent)

Application No.: Unknown

Examiner: P. Mertz (parent)

Filed: October 10, 2000

Attorney Dkt. No.: P100564-08026

For: A METHOD OF TREATMENT WITH GROWTH/DIFFERENTIATION FACTORS OF
THE TGF- β FAMILY

NOTIFICATION OF CHANGE OF NAME AND ADDRESS

Commissioner of Patents
Washington, D.C. 20231

October 10, 2000

Sir:


Kindly change the correspondence name and address for the above-identified
application to the following:

ARENT FOX KINTNER PLOTKIN & KAHN PLLC
1050 Connecticut Avenue, N.W., Suite 600
Washington, D.C. 20036-5339
Telephone: (202) 857-6000
Telefax: (202) 638-4810

Should any fees be due with respect to this paper, please charge Counsel's Deposit

Account No. 01-2300.

Respectfully submitted,
ARENT FOX KINTNER PLOTKIN & KAHN PLLC


Robert B. Murray
Attorney for Applicants
Registration No. 22,980

Attorney Docket No. P100564-00030
1050 Connecticut Avenue, N.W., Suite 600
Washington, D.C. 20036-5339
Tel: (202) 638-5000
Fax: (202) 638-4810

RBM:cb

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: HÖTTEN, Gertrud
NEIDHARDT, Helge
BECHTOLD, Rolf
POHL, Jens

(ii) TITLE OF INVENTION: DNA SEQUENCES ENCODING NOVEL
GROWTH/DIFFERENTIATION FACTORS

(iii) NUMBER OF SEQUENCES: 6

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: NIKAIDO, MARMELSTEIN, MURRAY & ORAM
(B) STREET: 655 Fifteenth Street, N. W., G Street Lobby,
Suite 330
(C) CITY: Washington
(D) STATE: DC
(E) COUNTRY: USA
(F) ZIP: 20005

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: UNKNOWN
(B) FILING DATE: 12-JUL-1996
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: KLESNER, Sharon N
(B) REGISTRATION NUMBER: 36,335
(C) REFERENCE/DOCKET NUMBER: P564-5010

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 202/638-5000
(B) TELEFAX: 202/638-4810

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2272 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(x) PUBLICATION INFORMATION:

(H) DOCUMENT NUMBER: US 08/289,222

(I) FILING DATE: 12-AUG-1994

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CAAGGAGCCA TGCCAGCTGG ACACACACTT CTTCCAGGGC CTCTGGCAGC CAGGACAGAG	60
TTGAGACCAC AGCTGTTGAG ACCCTGAGCC CTGAGTCTGT ATTGCTCAAG AAGGGCCTTC	120
CCCAGCAATG ACCTCCTCAT TGCTTCTGGC CTTTCTCCTC CTGGCTCCAA CCACAGTGGC	180
CACTCCCAGA GCTGGCGGTC AGTGTCAGC ATGTGGGGGG CCCACCTTGG AACTGGAGAG	240
CCAGCGGGAG CTGCTTCTTG ATCTGGCCAA GAGAAGCATC TTGGACAAGC TGCACCTCAC	300
CCAGCGCCCA AACTGAACC GCCCTGTGTC CAGAGCTGCT TTGAGGACTG CACTGCAGCA	360
GCTCCACGGG GTCCACAGG GGGCACTTCT AGAGGACAAC AGGGAACAGG AATGTGAAAT	420
CATCAGCTTT GCTGAGACAG GCCTCTCCAC CATCAACCAG ACTCGTCTTG ATTTTCACTT	480
CTCCTCTGAT AGAACTGCTG GTGACAGGGA GGTCCAGCAG GCCAGTCTCA TGTCTTTTGT	540
GCAGCTCCCT TCCAATACCA CTTGGACCTT GAAAGTGAGA GTCCTTGTGC TGGGTCCACA	600
TATATACCAAC CTCACCTTGG CTACTCAGTA CCTGCTGGAG GTGGATGCCA GTGGCTGGCA	660
TCAACTCCCC CTAGGGCCTG AAGCTCAAGC TGCCTCAGC CAGGGGCACC TGACCCTGGA	720
GCTGGTACTT GAAGGCCAGG TAGCCAGAG CTCAGTCATC CTGGGTGGAG CTGCCCATAG	780
GCCTTTTGTG GCAGCCCGGG TGAGAGTTGG GGGCAAACAC CAGATTCAAC GACGAGGCAT	840
CGACTGCCAA GGAGGCTCCA GGATGTGCTG TCGACAAGAG TTTTTTGTGG ACTTCCGTGA	900
GATTGGCTCG CACCACTGGA TCATCCAGCC TGAGGGCTAC GCCATGAACT TCTGCATAGG	960
GCAGTGCCCA CTACACATAG CAGGCATGCC TGGTATTGCT GCCTCCTTTC AACTGCAGT	1020
GCTCAATCTT CTCAAGGCC ACACAGCTGC AGGCACCACT GGAGGGGGCT CATGCTGTGT	1080
ACCCACGGCC CGGCGCCCCC TGTCTCTGCT CTATTATGAC AGGGACAGCA ACATTGTCAA	1140
GA CTGACATA CCTGACATGG TAGTAGAGGC CTGTGGGTGC AGTTAGTCTA TGTGTGGTAT	1200
GGGCAGCCCA AGGTTGCATG GAAAAACAG CCCCTACAGA AGTGCACCTC CTTGAGAGGA	1260
GGGAATGACC TCATTCTCTG TCCAGAATGT GGACTCCCTC TTCCTGAGCA TCTTATGGAA	1320
ATTACCCAC CTTTGACTTG AAGAAACCTT CATCTAAAGC AAGTCACTGT GCCATCTTCC	1380

TGACCACTAC CCTCTTTCCT AGGGCATAGT CCATCCCGCT AGTCCATCCC GCTAGCCCCA 1440
 CTCCAGGGAC TCAGACCCAT CTCCAACCAT GAGCAATGCC ATCTGGTTCC CAGGCAAAGA 1500
 CACCCTTAGC TCACCTTTAA TAGACCCCAT AACCCTACTAT GCCTTCCTGT CCTTCTACT 1560
 CAATGGTCCC CACTCCAAGA TGAGTTGACA CAACCCCTTC CCCCAATTTT TGTGGATCTC 1620
 CAGAGAGGCC CTTCTTTGGA TTCACCAAAG TTTAGATCAC TGCTGCCCAA AATAGAGGCT 1680
 TACCTACCCC CCTCTTTGTT GTGAGCCCTT GTCCCTCTTA GTTGTCCAGG TGAACACTA 1740
 AGCTCTCTT TGCATACCTT CATCCATTTT TTGTCTTCT CTGCCTTCT CTATGCCCTT 1800
 AGGGGTGAC TTGCCTGAGC TCTATCACCT GAGCTCCCCT GCCCTCTGGC TTCCTGCTGA 1860
 GGTGAGGCA TTTCTTATCC CTGTTCCCTC TCTGTCTAGG TGTCATGGTT CTGTGTAAC 1920
 GTGGCTATTC TGTGTCCCTA CACTACCTGG CTACCCCTT CCATGGCCCC AGCTCTGCCT 1980
 ACAITCTGAT TTTTTTTTTT TTTTTTTTTT TGAAAAGTTA AAAATTCCTT AATTTTTTAT 2040
 TCCTGGTACC ACTACCACAA TTTACAGGGC AATATACCTG ATGTAATGAA AAGAAAAAGA 2100
 AAAAGACAAA GCTACAACAG ATAAAAGACC TCAGGAATGT ACATCTAATT GACACTACAT 2160
 TCATTAAATC AATAGCTGCA CTTTTTGCAA ACTGTGGCTA TGACAGTCTT GAACAAGAAG 2220
 GGTTCCTGT TTAAGCTGCA GTAACCTTTC TGACTATGGA TCATCGTTCC TT 2272

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 352 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(x) PUBLICATION INFORMATION:

- (H) DOCUMENT NUMBER: US 08/289,222
- (I) FILING DATE: 12-AUG-1994

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met	Thr	Ser	Ser	Leu	Leu	Leu	Ala	Phe	Leu	Leu	Leu	Ala	Pro	Thr	Thr
1				5					10					15	
Val	Ala	Thr	Pro	Arg	Ala	Gly	Gly	Gln	Cys	Pro	Ala	Cys	Gly	Gly	Pro
			20				25						30		

Thr Leu Glu Leu Glu Ser Gln Arg Glu Leu Leu Leu Asp Leu Ala Lys
 35 40 45
 Arg Ser Ile Leu Asp Lys Leu His Leu Thr Gln Arg Pro Thr Leu Asn
 50 55 60
 Arg Pro Val Ser Arg Ala Ala Leu Arg Thr Ala Leu Gln His Leu His
 65 70 75 80
 Gly Val Pro Gln Gly Ala Leu Leu Glu Asp Asn Arg Glu Gln Glu Cys
 85 90 95
 Glu Ile Ile Ser Phe Ala Glu Thr Gly Leu Ser Thr Ile Asn Gln Thr
 100 105 110
 Arg Leu Asp Phe His Phe Ser Ser Asp Arg Thr Ala Gly Asp Arg Glu
 115 120 125
 Val Gln Gln Ala Ser Leu Met Phe Phe Val Gln Leu Pro Ser Asn Thr
 130 135 140
 Thr Trp Thr Leu Lys Val Arg Val Leu Val Leu Gly Pro His Asn Thr
 145 150 155 160
 Asn Leu Thr Leu Ala Thr Gln Tyr Leu Leu Glu Val Asp Ala Ser Gly
 165 170 175
 Trp His Gln Leu Pro Leu Gly Pro Glu Ala Gln Ala Ala Cys Ser Gln
 180 185 190
 Gly His Leu Thr Leu Glu Leu Val Leu Glu Gly Gln Val Ala Gln Ser
 195 200 205
 Ser Val Ile Leu Gly Gly Ala Ala His Arg Pro Phe Val Ala Ala Arg
 210 215 220
 Val Arg Val Gly Gly Lys His Gln Ile His Arg Arg Gly Ile Asp Cys
 225 230 235 240
 Gln Gly Gly Ser Arg Met Cys Cys Arg Gln Glu Phe Phe Val Asp Phe
 245 250 255
 Arg Glu Ile Gly Trp His Asp Trp Ile Ile Gln Pro Glu Gly Tyr Ala
 260 265 270
 Met Asn Phe Cys Ile Gly Gln Cys Pro Leu His Ile Ala Gly Met Pro
 275 280 285
 Gly Ile Ala Ala Ser Phe His Thr Ala Val Leu Asn Leu Leu Lys Ala
 290 295 300
 Asn Thr Ala Ala Gly Thr Thr Gly Gly Gly Ser Cys Cys Val Pro Thr

[illegible]

TATCGATTGC CAGGGGGGGT CCAGGATGTG CTGTCGACAA GAGTTTTTTTG TAGACTTCCG 900
 TGAGATTGGC TGGAATGACT GGATCATCCA GCCTGAAGGC TATGCCATGA ACTTCTGCAC 960
 TGGGCAGTGC CCACTACATG TGGCAGGCAT GCCTGGCATC TCTGCCTCCT TTCACACTGC 1020
 AGTGCTGAAT CTGCTCAAAG CCAACGCAGC TGCTGGCACC ACTGGCAGGG GCTCGTGCTG 1080
 CGTGCCTACA TCTCGGCGCC CTCTGTCTTT GCTCTACTAT GACAGGGACA GCAACATTGT 1140
 CAAGACGGAT ATACCTGACA TGGTGGTCCA GGCTGCGGG TGTAGTTAGC TTATGGGTGA 1200
 TACAGGCTGC CTGAGGTAGA ATGGCCTTCC TCAGGAAGGG AAACCTCTGTT CCCACTTCTG 1260
 TCCAGAATGG AAACACCTTT CTAAGCATGC AGACATCCCT CTGTGGACTT CAGGGGATCC 1320
 ACCTCTAAAG AGAGTCACTA GTGACCAACA GCCTTTCTCT CTCCTGGGAC ATGGTTGACC 1380
 CAGTACACCC ATCCTCAGCC TTAAGTTAGA GGCTAATCGA CTCCTACATA TATATGTCAT 1440
 TTGTCTCTAG CAAACACCCC TTAGCTCCCC TTAGTCAACT ATGTAATCTA CTCTGCCTCC 1500
 CTGACCCTGC CACCGGAAGG TTCTATTCC ACGATGATAT GCCTTAGTGT CTCCCCTT 1558

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 352 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(x) PUBLICATION INFORMATION:

- (II) DOCUMENT NUMBER: US 08/289,222
- (I) FILING DATE: 12-AUG-1994

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met	Ala	Ser	Ser	Leu	Leu	Ala	Leu	Phe	Leu	Thr	Pro	Thr	Thr
1				5			10				15		
Val	Val	Asn	Pro	Lys	Thr	Glu	Gly	Pro	Cys	Pro	Ala	Cys	Trp
			20				25				30		Gly
Ile	Phe	Asp	Leu	Glu	Ser	Gln	Arg	Glu	Leu	Leu	Leu	Asp	Leu
		35					40					45	Ala
													Lys

Lys Ser Ile Leu Asp Lys Leu His Leu Ser Gln Arg Pro Ile Leu Ser
 50 55 60
 Arg Pro Val Ser Arg Gly Ala Leu Lys Thr Ala Leu Gln Arg Leu Arg
 65 70 75 80
 Gly Pro Arg Arg Glu Thr Leu Leu Glu His Asp Gln Arg Gln Glu Glu
 85 90 95
 Tyr Glu Ile Ile Ser Phe Ala Asp Thr Asp Leu Ser Ser Ile Asn Gln
 100 105 110
 Thr Arg Leu Glu Phe His Phe Ser Gly Arg Met Ala Ser Gly Met Glu
 115 120 125
 Val Arg Gln Thr Arg Phe Met Phe Phe Val Gln Phe Pro His Asn Ala
 130 135 140
 Thr Gln Thr Met Asn Ile Arg Val Leu Val Leu Arg Pro Tyr Asp Thr
 145 150 155 160
 Asn Leu Thr Leu Thr Ser Gln Tyr Val Val Gln Val Asn Ala Ser Gly
 165 170 175
 Trp Tyr Gln Leu Leu Leu Gly Pro Glu Ala Gln Ala Ala Cys Ser Gln
 180 185 190
 Gly His Leu Thr Leu Glu Leu Val Pro Glu Ser Gln Val Ala His Ser
 195 200 205
 Ser Leu Ile Leu Gly Trp Phe Ser His Arg Pro Phe Val Ala Ala Gln
 210 215 220
 Val Arg Val Glu Gly Lys His Arg Val Arg Arg Arg Gly Ile Asp Cys
 225 230 235 240
 Gln Gly Gly Ser Arg Met Cys Cys Arg Gln Glu Phe Phe Val Asp Phe
 245 250 255
 Arg Glu Ile Gly Trp Asn Asp Trp Ile Ile Gln Pro Glu Gly Tyr Ala
 260 265 270
 Met Asn Phe Cys Thr Gly Gln Cys Pro Leu His Val Ala Gly Met Pro
 275 280 285
 Gly Ile Ser Ala Ser Phe His Thr Ala Val Leu Asn Leu Leu Lys Ala
 290 295 300
 Asn Ala Ala Ala Gly Thr Thr Gly Arg Gly Ser Cys Cys Val Pro Thr
 305 310 315 320

Ser	Arg	Arg	Pro	Leu	Ser	Leu	Leu	Tyr	Tyr	Asp	Arg	Asp	Ser	Asn	Ile
				325					330					335	
Val	Lys	Thr	Asp	Ile	Pro	Asp	Met	Val	Val	Glu	Ala	Cys	Gly	Cys	Ser
			340					345					350		

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (x) PUBLICATION INFORMATION:
 - (H) DOCUMENT NUMBER: US 08/289,222
 - (I) FILING DATE: 12-AUG-1994
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CAGGTAGGTC CATGGTCG

18

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (B) LOCATION: 21
 - (D) OTHER INFORMATION: /note= "XAA IS T OR C"
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (B) LOCATION: 27
 - (D) OTHER INFORMATION: /note= "XAA IS A OR G"
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (B) LOCATION: 33
 - (D) OTHER INFORMATION: /note= "XAA IS A, C, T OR G"

(x) PUBLICATION INFORMATION:

(H) DOCUMENT NUMBER: US 08/289,222

(I) FILING DATE: 12-AUG-1994

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CTTGATTTT AACAGACC

18

[illegible]